Protein C deficiency is a hereditary or acquired thrombophilic disorder in which reduced levels or function of protein C impair the inactivation of factors Va and VIIIa, leading to an increased risk of venous thromboembolism.

Protein C Deficiency

2. Epidemiology

Parameter	Detail
Prevalence in general population	0.14–0.5% (approximately 1 in 200 to 1 in 500) ^[1]
Prevalence among patients with first VTE	~3–5%
Prevalence among patients with recurrent unprovoked VTE	Up to 5–8%
Heterozygous state	Vast majority of clinically encountered cases
Homozygous/compound heterozygous state	Extremely rare (~1 in 500,000 to 1 in 750,000 live births); presents in neonatal period

Protein C deficiency is even more common than antithrombin deficiency (0.02–0.2%) but less common than Protein S deficiency (~0.9%) as an inherited thrombophilia. ^[1]

Inherited Thrombophilia	Approximate Odds Ratio for VTE
Antithrombin deficiency	Up to 16.3 (most severe)
Protein C deficiency	~7.5
Protein S deficiency	~5.4
Factor V Leiden (heterozygous)	~3–7
Prothrombin G20210A (heterozygous)	~2–3

Antithrombin deficiency is the most clinically severe inherited thrombophilia. Protein C deficiency has an OR for thrombosis of approximately 7.5, intermediate between antithrombin deficiency (16.3) and protein S deficiency (5.4). ^[1]

3. Anatomy and Function: The Protein C Anticoagulant Pathway

The activation of Protein C is dependent on: ^[1]

Vitamin K (for proper synthesis/γ-carboxylation)
Thrombin (the key activator)

The activation pathway is beautifully self-regulating:

Thrombin (IIa) + Thrombomodulin (TM, on endothelial surface)
                    ↓
            Thrombin-TM complex
                    ↓
     Activates Protein C → Activated Protein C (APC)
                    ↓
    [Enhanced by Endothelial Protein C Receptor (EPCR)]

Why is this elegant? Thrombin is the central enzyme of the coagulation cascade that promotes clotting. But when thrombin binds to thrombomodulin on intact endothelial cells, it switches roles — it now activates Protein C, which is an anticoagulant. This is one of the body's built-in negative feedback loops: the more thrombin is generated, the more Protein C is activated, putting the brakes on coagulation.

4. Etiology

Protein C deficiency has autosomal dominant inheritance. ^[1]

Over 330 mutations in the PROC gene have been identified. These are classified into two types:

	Type I (Quantitative)	Type II (Qualitative)
Mechanism	Reduced synthesis or increased clearance → low antigen AND low activity	Normal amount of protein produced, but it is dysfunctional → normal antigen, low activity
Protein C antigen level	↓ Low	Normal
Protein C activity level	↓ Low	↓ Low
Frequency	More common (~80% of hereditary cases)	Less common (~20%)
Genetics	Various missense, nonsense, frameshift, splice-site mutations	Missense mutations affecting the active site or substrate-binding domain

Two types of Protein C deficiency exist: Type I and Type II. ^[1]

Heterozygous Protein C deficiency:

Protein C levels typically 30–65% of normal (normal range ~70–140%)
Variable penetrance — not all heterozygous individuals develop thrombosis (lifetime risk ~50%)
First VTE usually occurs between ages 10–50, often provoked by an additional risk factor (surgery, immobilisation, pregnancy, OCP use)

Homozygous or compound heterozygous Protein C deficiency:

Protein C levels < 1% (virtually undetectable)
Presents at birth with purpura fulminans — a devastating condition of widespread microvascular thrombosis with haemorrhagic skin necrosis
Fatal without immediate treatment (Protein C concentrate replacement + anticoagulation)

This is actually more common in clinical practice than the inherited form. Causes include:

Cause	Mechanism
Liver disease (cirrhosis, acute liver failure)	Reduced hepatic synthesis of Protein C
Vitamin K deficiency	Impaired γ-carboxylation → dysfunctional Protein C
Warfarin therapy	Warfarin inhibits vitamin K epoxide reductase → impairs γ-carboxylation of vitamin K–dependent factors including Protein C (this has major clinical significance — see warfarin-induced skin necrosis below)
DIC (Disseminated Intravascular Coagulation)	Consumption of Protein C in widespread microthrombosis
Acute thrombosis	All three natural anticoagulants (Protein C, S, AT) are consumed in the clot during acute thrombosis ^[1]
Sepsis/severe infection (especially meningococcal septicaemia)	Consumption + endothelial damage → reduced thrombomodulin → reduced Protein C activation
L-asparaginase therapy (for ALL)	Reduced hepatic protein synthesis
Nephrotic syndrome	Urinary loss of Protein C
Pregnancy	Protein C levels may change across trimesters (generally decrease slightly in third trimester)
Post-operative state	Consumption + haemodilution

Under normal circumstances, levels of natural anticoagulants in our body change over time — in pregnancy, levels change in different trimesters; childhood has different reference ranges. ^[1]

Warfarin-Induced Skin Necrosis

Warfarin-induced skin necrosis is a rare but feared complication that occurs in patients with Protein C deficiency (or, less commonly, Protein S deficiency). ^[2]

Why does this happen?

Warfarin inhibits vitamin K–dependent factors: II, VII, IX, X (procoagulant) AND Protein C and Protein S (anticoagulant)
Protein C has a very short half-life (~6–8 hours) — similar to Factor VII (~4–6 hours) — much shorter than Factors II (~60 hours), IX (~24 hours), and X (~36 hours)
When warfarin is initiated, Protein C levels fall rapidly (within hours), but the procoagulant factors (especially II and X) remain elevated for 2–3 days
This creates a transient hypercoagulable state in the first 3–5 days of warfarin therapy
In patients who already have low Protein C (heterozygous deficiency), this transient state is exaggerated, leading to microvascular thrombosis in skin and subcutaneous fat → haemorrhagic skin necrosis
This is why warfarin should always be bridged with heparin (UFH or LMWH) when initiating therapy, and warfarin should never be started without concurrent parenteral anticoagulation

5. Pathophysiology

6. Classification

	Inherited	Acquired
Mechanism	Mutations in PROC gene	Reduced synthesis, increased consumption, or drug-induced
Inheritance	Autosomal dominant ^[1]	N/A
Onset	Young age (10–50 years, or neonatal if homozygous)	Any age; often in the context of an underlying condition
Examples	Type I, Type II (see below)	Liver disease, warfarin, DIC, sepsis, vitamin K deficiency

	Type I (Quantitative)	Type II (Qualitative/Functional)
Protein C antigen	↓	Normal
Protein C activity	↓	↓
Mechanism	Reduced production or increased degradation	Dysfunctional molecule
Frequency	~80% of inherited cases	~20% of inherited cases

	Heterozygous	Homozygous / Compound Heterozygous
Protein C level	~30–65% of normal	< 1%
Clinical severity	Variable; many asymptomatic; VTE risk especially with additional risk factors	Severe; neonatal purpura fulminans
Inheritance pattern	One mutant allele from one parent	Two mutant alleles (one from each parent)
Prevalence	~1 in 200–500	~1 in 500,000–750,000

7. Clinical Features

7.1 Symptoms

Many heterozygous individuals are asymptomatic throughout life. Symptoms, when they occur, are related to venous thromboembolism:

Symptom	Pathophysiological Basis
Unilateral leg swelling, pain, warmth (DVT)	Thrombus in deep veins of the lower limb → venous outflow obstruction → hydrostatic pressure increases distal to the clot → fluid transudation into interstitial space → oedema; venous wall inflammation → pain
Sudden-onset dyspnoea, pleuritic chest pain, haemoptysis (PE)	DVT embolises to pulmonary vasculature → mechanical obstruction of pulmonary arterial flow → V/Q mismatch → hypoxaemia → dyspnoea; pulmonary infarction → pleuritic pain and haemoptysis
Recurrent VTE (unprovoked or with minimal provocation)	Persistent hypercoagulable state → ongoing tendency to form venous thrombi, especially when compounded by additional risk factors (immobilisation, surgery, pregnancy, OCP)
VTE at unusual sites: cerebral venous sinus thrombosis, mesenteric/portal/renal vein thrombosis	Hypercoagulability affects the entire venous system; these sites have relatively lower flow and are susceptible
Recurrent miscarriages (in women)	Placental microvascular thrombosis → placental insufficiency → fetal loss (though this is more classically associated with APLS; some data supports an association with Protein C deficiency)

Key history points that raise suspicion:

Young age at first VTE (< 45 years) without clear provocation
Family history of VTE — autosomal dominant inheritance means multiple family members across generations may be affected ^[1]
VTE occurring with minimal provocation (e.g. short flight, minor injury) or unprovoked
VTE at unusual sites (cerebral, mesenteric, portal, renal veins)
Warfarin-induced skin necrosis — a critical historical clue

Symptom	Pathophysiological Basis
Purpura fulminans in the neonate (within hours to days of birth)	Near-zero Protein C → uncontrolled thrombin generation → widespread microvascular thrombosis → haemorrhagic skin necrosis. The skin's end-artery supply is particularly vulnerable to microvascular occlusion
Neonatal DIC	Massive consumption of clotting factors and platelets secondary to widespread microthrombosis
Cerebral thrombosis	Microvascular thrombosis in cerebral vessels → neonatal stroke
Ophthalmological involvement	Retinal vessel thrombosis → visual impairment

Sign	Pathophysiological Basis
Unilateral leg oedema, erythema, warmth (DVT)	Venous outflow obstruction → increased hydrostatic pressure → oedema; inflammatory mediator release from thrombosed vein wall → erythema and warmth
Positive Homan's sign (calf pain on dorsiflexion)	Stretching of the thrombosed deep calf veins → pain; note: this sign is neither sensitive nor specific and is not relied upon diagnostically
Tachycardia, tachypnoea, hypoxia, right heart strain (PE)	Large PE → acute right ventricular (RV) pressure overload → RV dilatation and failure → reduced cardiac output → compensatory tachycardia; V/Q mismatch → hypoxaemia → tachypnoea
Raised JVP, loud P2 (massive PE)	RV failure → back-pressure into systemic veins → raised JVP; pulmonary hypertension → louder pulmonary component of S2
Warfarin-induced skin necrosis (heterozygous, typically)	Ecchymotic patches (especially on fatty areas: breasts, buttocks, thighs, abdomen) → rapidly progressing to full-thickness haemorrhagic necrosis. Occurs 3–5 days after warfarin initiation without heparin bridging
Purpura fulminans (homozygous neonates)	Widespread ecchymoses → rapidly coalescing into large, painful, indurated areas of skin with central black necrosis. Sharply demarcated borders. DIC features: petechiae, oozing from puncture sites
Post-thrombotic syndrome (chronic DVT complication)	After DVT resolution, damaged venous valves → chronic venous insufficiency → leg oedema, skin pigmentation (haemosiderin), lipodermatosclerosis, venous ulceration (classically around medial malleolus)

Clinical Pearl

When to suspect Protein C deficiency at the bedside:

A young patient ( < 45 years) with unprovoked DVT/PE
A patient with recurrent VTE despite adequate anticoagulation compliance
VTE at unusual sites (cerebral, mesenteric, portal, renal veins)
Family history of VTE across multiple generations (autosomal dominant)
Warfarin-induced skin necrosis ^[2] — this should immediately trigger consideration of Protein C (or Protein S) deficiency
Neonatal purpura fulminans → think homozygous Protein C deficiency

8. Thrombophilia Screening — When and How

Test	Result in Isolated Protein C Deficiency
PT	Normal
APTT	Normal
Fibrinogen	Normal
D-dimer	Normal (unless acute thrombosis is present)
Platelet count	Normal
Protein C activity	↓ (the key diagnostic test)
Protein C antigen	↓ (Type I) or Normal (Type II)

This means that standard coagulation screening (PT, APTT) will NOT detect Protein C deficiency — you must specifically order Protein C levels.

9. Integration with Coagulation Cascade Concepts

System	Target	Mechanism
Protein C/S	Factor Va, Factor VIIIa	Proteolytic cleavage by APC (Protein S as cofactor)
Antithrombin (AT)	Thrombin (IIa), Factor Xa, IXa, XIa, XIIa	Serine protease inhibitor (serpin); enhanced by heparin
Tissue Factor Pathway Inhibitor (TFPI)	Factor Xa, TF-VIIa complex	Inhibits initiation phase of coagulation

Connecting the Dots

Understanding why heparin works alongside the anticoagulant systems: Unfractionated heparin (UFH) works by enhancing antithrombin's activity 1000-fold. Low-molecular-weight heparin (LMWH) preferentially enhances antithrombin's inhibition of Factor Xa. These are the parenteral anticoagulants used to bridge patients when initiating warfarin — specifically to prevent warfarin-induced skin necrosis in Protein C–deficient patients by providing anticoagulant cover during the initial transient hypercoagulable window.

Feature	Detail
Definition	Inherited or acquired deficiency of Protein C → hypercoagulable state → VTE
Inheritance	Autosomal dominant (heterozygous); autosomal recessive phenotype (homozygous)
Gene	PROC on chromosome 2q14.3
Types	Type I (quantitative, ↓ antigen + activity) vs Type II (qualitative, normal antigen, ↓ activity)
Prevalence	~1 in 200–500 (general population)
Function	APC + Protein S → inactivates Factor Va and VIIIa → ↓ thrombin generation
Clinical presentation	VTE (DVT/PE), unusual-site thrombosis, recurrent VTE, warfarin-induced skin necrosis, neonatal purpura fulminans (homozygous)
Standard coag tests	PT and APTT are normal — must specifically order Protein C activity levels
Thrombophilia screening timing	Not during acute thrombosis or while on anticoagulants
Hong Kong relevance	Factor V Leiden and PT G20210A rare in Chinese → Protein C/S/AT deficiency relatively more important

High Yield Summary

Protein C is a vitamin K–dependent natural anticoagulant synthesized in the liver. When activated by thrombin-thrombomodulin complex, it (with cofactor Protein S) inactivates Factor Va and Factor VIIIa, putting the brakes on thrombin generation.
Inherited Protein C deficiency is autosomal dominant; prevalence ~1 in 200–500; OR for VTE ~7.5 (intermediate severity: AT deficiency > Protein C deficiency > Protein S deficiency).
Two types: Type I (quantitative — ↓ antigen and activity) and Type II (qualitative — normal antigen, ↓ activity).
Heterozygous patients present with VTE (DVT, PE, unusual-site thrombosis) typically at a young age (10–50 years). Homozygous patients present as neonates with purpura fulminans.
Warfarin-induced skin necrosis is a classic association — caused by rapid depletion of Protein C (short half-life ~6–8 hours) before procoagulant factors fall → transient hypercoagulable state. Always bridge with heparin when starting warfarin.
Standard PT/APTT are normal in isolated Protein C deficiency. Must specifically order Protein C activity (and antigen for typing).
Do not screen for thrombophilia during acute thrombosis or while on anticoagulants — levels are falsely affected.
In Hong Kong/Chinese populations, Factor V Leiden and Prothrombin G20210A are extremely rare → Protein C, Protein S, and Antithrombin deficiencies carry relatively greater diagnostic importance among inherited thrombophilias.

Active Recall - Protein C Deficiency

Differential Diagnosis of Protein C Deficiency

When you encounter a clinical scenario that raises suspicion for Protein C deficiency — typically a young patient with unprovoked VTE, a neonate with purpura fulminans, or a patient who develops skin necrosis on warfarin — you need a systematic framework. The differential diagnosis operates on two levels:

What else could be causing this patient's hypercoagulable state / VTE? (i.e. the differential of thrombophilia)
What else could cause a low Protein C level on laboratory testing? (i.e. the differential of a low Protein C result — inherited vs acquired)

Both are clinically important and are explored below.

Level 1: Differential Diagnosis of the Thrombophilic State (Why is this patient clotting?)

When a patient presents with features suggesting thrombophilia (young-onset VTE, recurrent VTE, unusual-site thrombosis, positive family history, warfarin-induced skin necrosis), the differential includes inherited and acquired causes of hypercoagulability. Think of these as conditions that shift the haemostatic balance towards excessive clot formation.

These are all conditions where there is a genetic defect in one of the body's natural anticoagulant or fibrinolytic pathways. They share certain features: autosomal dominant inheritance (except rare homozygous states), predilection for venous thrombosis, and presentation at a young age.

Condition	Mechanism	Prevalence	OR for VTE	Key Distinguishing Features
Protein C deficiency	Inadequate inactivation of Factor Va and VIIIa → excess thrombin generation	0.14–0.5% (1 in 200–500) ^[1]	~7.5 ^[1]	Associated with warfarin-induced skin necrosis; homozygous → neonatal purpura fulminans ^[1] ^[2]
Protein S deficiency	Protein S is a cofactor for activated Protein C → loss of Protein S means APC cannot function effectively → same downstream effect (Factor Va/VIIIa not inactivated) ^[1]	~0.9% ^[1]	~5.4 ^[1]	3 types (Type I, II, III); lab reports total and free Protein S — free form is what we look at ^[1]; also vitamin K–dependent; also associated with warfarin-induced skin necrosis
Antithrombin (AT) deficiency	AT normally inhibits thrombin, Factor Xa, IXa, XIa → loss of AT removes the main serpin-based brake on coagulation	0.02–0.2% (1 in 2000–5000) ^[1]	Up to 16.3 (most severe) ^[1]	VTE often resistant to normal doses of heparin (because heparin works by enhancing AT activity — if AT is deficient, heparin is less effective) ^[11]; most clinically severe inherited thrombophilia
Factor V Leiden (Activated Protein C Resistance)	R506Q mutation in Factor V → Factor Va resistant to cleavage by APC → functionally equivalent to Protein C deficiency	~5% in Caucasians; NOT found in Chinese ^[11]	~3–7 (hetero); ~80 (homo)	Extremely rare in Chinese/East Asian populations ^[11] — do NOT include this as a DDx in a Chinese patient in Hong Kong exams unless specifically asked about Caucasian populations
Prothrombin G20210A mutation	Gain-of-function mutation → increased prothrombin levels → excess thrombin generation	~2% in Caucasians; Very rare in Chinese ^[11]	~2–3	Same caveat as Factor V Leiden for Chinese populations
Dysfibrinogenaemia (rare)	Structurally abnormal fibrinogen → paradoxically can cause either bleeding or thrombosis	Very rare	Variable	Usually detected when thrombin time (TT) is prolonged; can cause both bleeding and thrombosis

Hong Kong Exam High Yield

In Chinese populations, Factor V Leiden is NOT found and Prothrombin G20210A is very rare. ^[11] This means the differential for inherited thrombophilia in a Hong Kong patient is essentially:

Protein C deficiency
Protein S deficiency
Antithrombin deficiency

These three are the "Big Three" inherited thrombophilias relevant to Chinese patients. Factor V Leiden and Prothrombin G20210A should generally NOT be included as differentials for a Chinese patient unless specifically asked. ^[11]

Condition	Mechanism	Key Distinguishing Features
Antiphospholipid syndrome (APLS)	Autoantibodies (lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein I) → activate endothelium, complement, and platelets → thrombosis. May occur as primary condition or secondary to underlying disease e.g. SLE ^[12]	Characterised by non-superficial vascular thrombosis + adverse pregnancy outcomes + persistent antiphospholipid antibodies on ≥2 occasions ≥12 weeks apart ^[12]; paradoxically prolongs APTT in vitro but causes thrombosis in vivo; recurrent miscarriage (especially 2nd/3rd trimester) ^[6]
Malignancy (occult or overt)	Tumour cells release tissue factor and mucin (especially adenocarcinoma) → activate extrinsic pathway; also cause endothelial damage and stasis	Most important cause of unprovoked VTE ^[11]; especially adenocarcinoma (pancreas, stomach, ovaries); myeloproliferative neoplasms ^[4]; Trousseau's syndrome (migratory thrombophlebitis)
Nephrotic syndrome	Massive proteinuria → urinary loss of natural anticoagulants (especially antithrombin) ^[1] ^[13]; loss of anticoagulants > loss of clotting factors → net procoagulant state	8× higher risk of VTE ^[13]; renal vein thrombosis is classic; chicken-and-egg with renal vein thrombosis causing proteinuria
Myeloproliferative neoplasms (MPN)	Polycythaemia vera → hyperviscosity; essential thrombocythaemia → platelet activation; all MPNs associated with JAK2 mutations driving cell proliferation	Splanchnic vein thrombosis (portal, hepatic/Budd-Chiari, mesenteric) is characteristic; check for splenomegaly, raised Hb/Hct, raised platelets
Paroxysmal nocturnal haemoglobinuria (PNH)	PIGA mutation → loss of GPI-anchored proteins (CD55/CD59) → complement-mediated haemolysis + platelet activation → thrombosis (especially Budd-Chiari syndrome, cerebral venous sinus thrombosis)	Haemolytic anaemia + pancytopenia + venous thrombosis at unusual sites; very rare
Hyperhomocysteinaemia	Elevated homocysteine damages endothelium → promotes thrombosis	Can be inherited (CBS deficiency) or acquired (B12/folate deficiency); no data in Chinese ^[11]
Pregnancy / post-partum	Physiological increase in clotting factors (especially fibrinogen, Factor VII, VIII, vWF); decreased Protein S; decreased fibrinolysis; venous stasis from uterine compression of IVC	Risk highest in 3rd trimester and post-partum period; must differentiate from APLS and inherited thrombophilia
OCP / HRT use	Oestrogens increase hepatic synthesis of clotting factors (II, VII, X, fibrinogen) and decrease Protein S and antithrombin	OC pills increase VTE risk 2–4× ^[6]; synergistic effect with inherited thrombophilia
Immobilisation / surgery / trauma	Stasis (Virchow's triad); endothelial injury; tissue factor release	The higher the level of thrombosis, the greater the risk of embolisation ^[14]; most common provoked cause of VTE
DIC (Disseminated Intravascular Coagulation)	Widespread activation of coagulation → consumption of factors AND natural anticoagulants (including Protein C) → simultaneous thrombosis and bleeding	Distinguished by ↑PT, ↑APTT, ↓fibrinogen, ↑D-dimer, ↓platelets, schistocytes on PBS ^[2]
Heparin-Induced Thrombocytopenia (HIT) Type II	Anti-PF4/heparin antibodies → platelet activation → thrombosis with paradoxical thrombocytopenia	Typically occurs 5–10 days after heparin initiation; thrombocytopenia (platelet drop > 50%) + new thrombosis while on heparin

Predisposing Causes of DVT and PE — Lecture Slide

Predisposing causes of DVT and PE include: Protein S and C deficiency, Anti-thrombin III deficiency (acquired or genetic predisposition); Immobility; Oestrogens; Hypercoagulable states from systemic disease e.g. Malignancy; Antiphospholipid syndrome / SLE; Nephrotic syndrome; Instrumentation to leg veins e.g. femoral catheterisation. ^[14]

A low Protein C activity result does not automatically mean the patient has inherited Protein C deficiency. You must consider acquired causes that lower Protein C levels before diagnosing an inherited condition. This is why thrombophilia screening should not be performed during acute thrombosis or while on anticoagulants ^[2].

Cause of Low Protein C	Mechanism	How to Distinguish from Inherited Deficiency
Acute thrombosis	All three natural anticoagulants are consumed in the clot ^[1]	Repeat testing ≥2–4 weeks after the acute event when patient is off anticoagulants
Warfarin therapy	Warfarin inhibits vitamin K–dependent γ-carboxylation → reduces functional Protein C	Withhold warfarin × 2 weeks before testing ^[2]; Protein C rises after warfarin cessation if the deficiency is drug-induced
Vitamin K deficiency	Same mechanism as warfarin — impaired γ-carboxylation	Clinical context (malnutrition, cholestasis, antibiotic-induced gut flora disruption); other vitamin K–dependent factors (II, VII, IX, X) also low; corrects with vitamin K administration
Liver disease (cirrhosis, acute liver failure)	Reduced hepatic synthesis of Protein C (and most other coagulation factors)	Other markers of synthetic liver failure (low albumin, prolonged PT, low Factor V); low Protein C is part of a global coagulopathy, not isolated
DIC	Consumption of Protein C in widespread microthrombosis	Classic DIC labs: ↑PT, ↑APTT, ↓fibrinogen, ↑D-dimer, ↓platelets, schistocytes ^[2]
Sepsis (especially meningococcal)	Endothelial damage → reduced thrombomodulin expression → reduced Protein C activation; consumption in microthrombosis	Clinical context of severe infection; may present with purpura fulminans (acquired, not inherited)
L-asparaginase therapy	Reduces hepatic protein synthesis broadly (used in ALL treatment)	Drug history; reversible on drug cessation
Nephrotic syndrome	Urinary loss of anticoagulant proteins including Protein C	Heavy proteinuria, hypoalbuminaemia, oedema
Pregnancy	Levels change in different trimesters ^[1]; slight decrease in 3rd trimester	Use pregnancy-specific reference ranges; recheck post-partum
Neonates/Infants	Different in childhood, have different reference ranges ^[1]; physiologically low in neonates	Use age-appropriate reference ranges; confirm with family testing and genetic analysis

Critical Exam Pitfall

Never diagnose inherited Protein C deficiency based on a single low level taken during an acute thrombotic event or while the patient is on warfarin/heparin/DOAC. The result is uninterpretable.

The approach:

Treat the acute VTE first (with heparin → warfarin/DOAC)
Test for inherited thrombophilia after the acute phase (≥2–4 weeks) and after stopping anticoagulants (warfarin × 2 weeks, DOAC × ≥2 days) ^[2]
Confirm an abnormal result with repeat testing on a separate occasion
Consider family screening (first-degree relatives) — if family members also have low Protein C, this strongly supports an inherited cause

Distinguishing Protein C Deficiency from Its Closest Mimics

Feature	Protein C Deficiency	Protein S Deficiency
Mechanism	Deficient serine protease (the "enzyme")	Deficient cofactor (the "helper" for Protein C)
Inheritance	Autosomal dominant ^[1]	Autosomal dominant ^[1]
Types	Type I, Type II ^[1]	Type I, Type II, Type III ^[1]
Vitamin K dependence	Yes	Yes
Prevalence	0.14–0.5% ^[1]	~0.9% ^[1]
OR for VTE	~7.5 ^[1]	~5.4 ^[1]
Warfarin-induced skin necrosis	Yes (classic association)	Yes (less commonly)
Lab distinction	Low Protein C activity ± antigen	Low free Protein S (free form is what we look at ^[1]); Protein C levels normal
Net effect	Factor Va/VIIIa not inactivated	Identical downstream effect (Factor Va/VIIIa not inactivated, because APC cannot function without its cofactor)

Feature	Protein C Deficiency	Antithrombin Deficiency
Target	Factor Va, VIIIa (cofactors)	Thrombin (IIa), Factor Xa, IXa, XIa (enzymes)
OR for VTE	~7.5 ^[1]	Up to 16.3 ^[1]
Response to heparin	Normal	VTE often resistant to normal doses of heparin ^[11] (because heparin requires AT to work)
Prevalence	0.14–0.5% ^[1]	0.02–0.2% ^[1]
Vitamin K dependent?	Yes	No (AT is not vitamin K–dependent)
Affected by warfarin?	Yes (warfarin lowers Protein C)	No (warfarin does not affect AT levels)

Feature	Protein C Deficiency	APLS
Nature	Inherited (or acquired secondary to liver/DIC)	Acquired autoimmune
Mechanism	Reduced anticoagulant activity	Autoantibodies activate endothelium + complement → thrombosis
Thrombosis type	Predominantly venous	Both venous AND arterial ^[12]
Pregnancy complications	Possible (placental microthrombosis)	Major feature: recurrent miscarriage, especially 2nd/3rd trimester ^[12]
APTT	Normal	Often prolonged (paradoxically, due to lupus anticoagulant interfering with phospholipid-dependent assays in vitro)
Lab diagnosis	Low Protein C activity	Positive lupus anticoagulant, anti-cardiolipin Ab, anti-β2-GPI Ab on ≥2 occasions ≥12 weeks apart ^[12]
Association	Family history of VTE	May occur as primary or secondary to SLE ^[12]; livedo reticularis, thrombocytopenia

DDx Category	Conditions	Key Discriminator from Protein C Deficiency
Other natural anticoagulant deficiencies	Protein S deficiency, Antithrombin deficiency	Specific assay for each protein; AT deficiency → heparin resistance; Protein S deficiency → low free Protein S with normal Protein C
Gain-of-function mutations	Factor V Leiden, Prothrombin G20210A	Not found / very rare in Chinese ^[11]; PCR-based genetic testing
Acquired autoimmune	APLS	Lupus anticoagulant, anti-cardiolipin, anti-β2-GPI; arterial + venous thrombosis; recurrent miscarriage
Malignancy-associated	Trousseau's syndrome, MPN	Age-appropriate cancer screening; JAK2 mutation, CBC for raised Hb/WCC/platelets
Nephrotic syndrome	Loss of AT (primarily) in urine	Heavy proteinuria, hypoalbuminaemia, oedema
Acquired low Protein C	Liver disease, warfarin, DIC, sepsis, vitamin K deficiency, L-asparaginase	Clinical context; concurrent abnormalities in PT, albumin, other coagulation factors; reversible when underlying cause treated
Heparin-induced thrombocytopenia (HIT II)	Anti-PF4/heparin Ab → platelet activation	Temporal relationship with heparin (5–10 days); thrombocytopenia + thrombosis on heparin; 4T score
PNH	Complement-mediated haemolysis + thrombosis	Flow cytometry showing absent CD55/CD59; haemolytic anaemia + pancytopenia

High Yield Summary — Differential Diagnosis

The "Big Three" inherited thrombophilias relevant to Hong Kong Chinese patients are Protein C deficiency, Protein S deficiency, and Antithrombin deficiency. Factor V Leiden and Prothrombin G20210A are essentially absent in Chinese populations.
Always exclude acquired causes of low Protein C (warfarin, liver disease, DIC, acute thrombosis, vitamin K deficiency, sepsis) before labelling a patient as having inherited Protein C deficiency.
APLS is the most important acquired thrombophilia to distinguish — it causes both arterial and venous thrombosis plus recurrent pregnancy loss, and is diagnosed by persistent antiphospholipid antibodies.
Malignancy is the single most important cause of unprovoked VTE overall — always consider occult malignancy screening in older patients with new VTE.
Warfarin-induced skin necrosis specifically points to Protein C (or Protein S) deficiency; heparin resistance specifically points to Antithrombin deficiency*.
Thrombophilia testing must be timed correctly: not during acute thrombosis, and not while on anticoagulants.

Active Recall - Protein C Deficiency: Differential Diagnosis

References

^[1] Senior notes: Block A - Leg swelling and chest pain: deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (Inherited thrombophilia sections on Protein C, Protein S, Antithrombin deficiency; Acquired deficiencies of natural anticoagulants; Nephrotic syndrome and thrombophilia) ^[2] Senior notes: Maksim Medicine Notes.pdf (Thrombophilia screening, DIC, purpura fulminans, p.165) ^[4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (DVT/PE etiology, inherited conditions) ^[6] Senior notes: Ryan Ho Respiratory.pdf (PE risk factors, inherited thrombophilia, OCP risk) ^[8] Senior notes: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf (Coagulation cascade, PT/APTT interpretation, D-dimer) ^[11] Senior notes: Adrian Lui Pediatrics Notes.pdf (Thrombophilia screening, inherited thrombophilia table, Factor V Leiden not in Chinese) ^[12] Senior notes: Ryan Ho Rheumatology.pdf (Antiphospholipid syndrome, Revised Sapporo criteria) ^[13] Senior notes: Block A - Leg swelling and chest pain: deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (Nephrotic syndrome and thrombophilia section) ^[14] Lecture slides: Respiratory Two cases of acute shortness of breath - case 1.pdf (Predisposing causes of DVT and PE)

Diagnostic Criteria, Diagnostic Algorithm and Investigation Modalities

1. Diagnostic Criteria for Protein C Deficiency

Unlike many conditions in medicine, there is no single universally codified "diagnostic criteria" set (like the Revised Sapporo criteria for APLS or the ACR criteria for SLE). Instead, the diagnosis of Protein C deficiency is established through a combination of clinical context, specific laboratory testing, exclusion of acquired causes, and confirmatory repeat testing ± genetic analysis. Let's walk through each component.

The diagnosis rests on measuring Protein C activity (a functional/chromogenic assay) and Protein C antigen (an immunological assay). Together these allow both diagnosis and typing.

Diagnostic Step	Requirement	Rationale
Step 1: Protein C activity	Below the lower limit of the age-appropriate reference range (typically < 70% in adults, though lab-specific cut-offs vary)	Activity assay captures both Type I (low production) and Type II (dysfunctional molecule). It is the primary screening test — if activity is normal, the patient does not have Protein C deficiency
Step 2: Protein C antigen	Ordered when activity is low	Distinguishes Type I (low antigen AND low activity) from Type II (normal antigen, low activity) ^[1]
Step 3: Exclude acquired causes	Ensure the patient is not on warfarin, not in acute thrombosis, not in DIC, has no liver failure, and has no vitamin K deficiency	Acute thrombosis → all three natural anticoagulants are consumed in the clot ^[1]; warfarin reduces Protein C (vitamin K–dependent) ^[2]; these give falsely low levels
Step 4: Confirmatory repeat testing	Repeat Protein C activity on a separate occasion (≥2–4 weeks later, off anticoagulants)	A single low level is insufficient for diagnosis — transient acquired causes must be excluded; biological variability exists
Step 5: Family screening	Test first-degree relatives for Protein C levels	If the proband and one or more first-degree relatives have concordantly low Protein C, this strongly supports autosomal dominant inheritance ^[1]
Step 6: Genetic testing (PROC gene)	Sequence the PROC gene on chromosome 2q14.3	Definitive confirmation; identifies the specific mutation; useful for genetic counselling and prenatal diagnosis in severe (homozygous) families; not routinely needed for all heterozygous cases

Practical Diagnostic Rule

You can diagnose inherited Protein C deficiency when:

Protein C activity is persistently low on at least two separate occasions, AND
Acquired causes of low Protein C have been excluded, AND
Ideally, a family member is also found to have low Protein C levels (supporting autosomal dominant pattern)

Genetic testing of PROC confirms the diagnosis definitively but is not always required for clinical management.

Parameter	Normal Adult Range	Heterozygous Protein C Deficiency	Homozygous Protein C Deficiency
Protein C activity	~70–140% (lab-specific)	~30–65%	< 1% (often undetectable)
Protein C antigen	~70–140%	↓ (Type I) or Normal (Type II)	< 1%

Important caveats:

Levels change throughout life — in pregnancy, levels change in different trimesters; childhood has different reference ranges ^[1]
Neonates physiologically have ~30–40% Protein C activity at birth (reaches adult levels by ~6 months)
Mild heterozygous deficiency may overlap with the lower end of the normal range → this is why repeat testing and family studies are essential

Thrombophilia screening indications: ^[2]

Young patients with idiopathic venous thrombosis
Suspected APLS, e.g. recurrent miscarriage
Unusual sites of thrombosis, e.g. mesenteric, renal, portal vein, cerebral venous sinus
Warfarin-induced skin necrosis (Protein C/S deficiency)

Timing: Do not test at time of VTE event, or while patients are receiving anticoagulants (withhold warfarin × 2 weeks, DOAC × at least 2 days). ^[2]

Situation	Why Testing Is Invalid	When to Test Instead
Acute VTE event	Natural anticoagulants consumed in clot ^[1]	≥2–4 weeks after acute event
On warfarin	Warfarin reduces vitamin K–dependent Protein C → false positive	Withhold warfarin × 2 weeks ^[2]; can bridge with LMWH if needed during testing window
On DOAC	May interfere with clot-based assays	Withhold DOAC × at least 2 days ^[2]
On heparin	Reduces antithrombin levels (relevant for AT testing, less for Protein C)	Withhold heparin ≥24 hours for UFH, ≥48 hours for LMWH
Active DIC	Consumption of all anticoagulant proteins	After DIC resolves
Active liver disease	Reduced hepatic synthesis of Protein C	Interpret with caution; concurrent LFT to assess liver synthetic function
Pregnancy	Physiological changes in Protein S (and mild changes in Protein C)	Test post-partum (≥6–8 weeks)

Exam Pitfall

A common exam trap: a patient presents with acute DVT, blood is drawn, and Protein C comes back low. You cannot diagnose inherited Protein C deficiency on this single result. The low level is likely due to consumption in the acute clot. You must treat the VTE first, then retest after ≥2–4 weeks off anticoagulants.

3. Investigation Modalities

The investigations for Protein C deficiency fall into three categories:

Specific Protein C assays (to diagnose and type the deficiency)
Thrombophilia panel (to assess for concurrent or alternative thrombophilias)
Baseline/supportive investigations (to assess the clinical consequences of the prothrombotic state and exclude acquired causes)

Investigation	Principle	What It Tells You	Key Findings
Protein C activity (functional/chromogenic assay)	Uses a snake venom activator (e.g. Protac) to activate Protein C in the sample, then measures the ability of activated Protein C to cleave a chromogenic substrate	Detects both Type I (low quantity) and Type II (dysfunctional) deficiency → the single best screening test	↓ in both Type I and Type II
Protein C activity (clot-based assay)	Measures Protein C function by its ability to prolong APTT in the presence of activated Protein C	Alternative functional assay; may be affected by Factor V Leiden (FVL causes APCR → can give falsely normal results) and lupus anticoagulant	Use chromogenic assay preferentially to avoid interference
Protein C antigen (immunological, e.g. ELISA)	Uses antibodies to quantitate the amount of Protein C protein in plasma, irrespective of function	Distinguishes Type I (low antigen) from Type II (normal antigen)	Type I: low antigen AND low activity; Type II: normal antigen, low activity ^[1]
PROC gene sequencing	Sanger sequencing or next-generation sequencing of the entire PROC gene (chromosome 2q14.3)	Identifies the causative mutation definitively; useful for genetic counselling, prenatal diagnosis, and family screening	> 330 mutations described; missense, nonsense, frameshift, splice-site variants

Which assay to order first? Always start with Protein C activity (chromogenic) — it is the most sensitive and least prone to interference. Only if activity is low, proceed to Protein C antigen for typing.

Thrombophilia screening tests include: Protein C, Protein S, activated protein C resistance (APCR), anti-thrombin (AT), Factor V Leiden PCR, Prothrombin G20210A mutation, and APLS markers (anti-cardiolipin, lupus anticoagulant, anti-β2-glycoprotein I antibody). ^[2]

Investigation	What It Detects	Key Interpretation Points
Protein C activity + antigen	Protein C deficiency	As above
Free Protein S (and total Protein S)	Protein S deficiency	When ordering, will receive results in total Protein S and free Protein S → the free form is what we are looking for ^[1]; Protein S is a cofactor for activated Protein C ^[1]
Antithrombin (AT) activity	Antithrombin deficiency	Most clinically severe inherited thrombophilia (OR up to 16.3) ^[1]; remember heparin enhances AT → if AT is deficient, VTE often resistant to normal doses of heparin ^[11]
Activated Protein C Resistance (APCR)	Functional screening for Factor V Leiden (and some other causes of APC resistance)	Measures whether the patient's plasma APTT prolongs normally when exogenous APC is added. If APTT does not prolong (i.e. "resistant"), suggests Factor Va is not being cleaved → extremely rare in Chinese populations ^[11]
Factor V Leiden PCR	Factor V Leiden mutation (R506Q)	Genetic test; NOT found in Chinese ^[11] — generally not indicated for Hong Kong Chinese patients unless specifically requested
Prothrombin G20210A mutation	Prothrombin gain-of-function mutation	Genetic test; Very rare in Chinese ^[11]
Lupus anticoagulant (LA)	APLS (antiphospholipid antibodies)	Screening tests: DRVVT (Dilute Russell Viper Venom Time) and aPTT-based LA screen; confirmatory: mixing studies and phospholipid neutralisation ^[8]
Anti-cardiolipin antibody (aCL)	APLS	IgG and IgM; moderate-to-high titre ( > 40 units) significant; must be positive on ≥2 occasions ≥12 weeks apart ^[12]
Anti-β2-glycoprotein I antibody	APLS	IgG and IgM; same temporal criteria as aCL

Hong Kong-Specific Testing Strategy

In Hong Kong Chinese patients, the inherited thrombophilia panel can be streamlined because Factor V Leiden and Prothrombin G20210A are essentially absent ^[11]. The core panel should focus on:

Protein C activity (± antigen)
Free Protein S
Antithrombin activity
APLS markers (acquired thrombophilia — still important in Chinese)

APCR/Factor V Leiden PCR and Prothrombin G20210A PCR can be omitted in ethnically Chinese patients unless there is mixed ancestry or a specific clinical indication.

These are the routine bedside coagulation tests. It is critical to understand that Protein C deficiency does NOT affect standard coagulation tests in isolation.

Test	Expected Result in Isolated Protein C Deficiency	Explanation	When Abnormalities Might Appear
Platelet count	Normal	Protein C is a plasma protein involved in the coagulation cascade, not in platelet production or function	Low platelets → think DIC, HIT, APLS with thrombocytopenia, TTP
Prothrombin Time (PT)	Normal	PT tests the extrinsic pathway (Factor VII → common pathway). Protein C does not participate directly in this test system	Elevated PT + vitamin K deficiency → think cholestasis (impaired bile → impaired fat absorption → impaired vitamin K absorption) ^[15]; elevated PT + liver disease → reduced synthesis of factors ^[15]
Activated Partial Thromboplastin Time (APTT)	Normal	APTT tests the intrinsic pathway (Factors XII, XI, IX, VIII → common pathway). Again, Protein C does not participate directly	Elevated APTT → think haemophilia, vWD, lupus anticoagulant, heparin use ^[2] ^[8]
Fibrinogen	Normal	Fibrinogen (Factor I) is consumed in DIC but is unaffected by Protein C deficiency per se	Low fibrinogen → DIC, liver failure, dysfibrinogenaemia
D-dimer	Normal (unless acute thrombosis present)	D-dimer is a product of fibrin degradation; it reflects active thrombosis/fibrinolysis, not the underlying cause	Elevated D-dimer → many causes: VTE, DIC, infection, malignancy, pregnancy, post-surgery ^[8]; sensitive but not specific ^[8]

You can do well on just platelet count, PT and APTT ^[15] — but for Protein C deficiency specifically, these will all be normal. You must specifically order Protein C levels; routine coagulation screening will miss the diagnosis entirely.

Critical Teaching Point

PT and APTT are NORMAL in isolated Protein C deficiency. This is a common source of false reassurance. A patient can have a lethal inherited thrombophilia with a completely normal coagulation screen. The lesson: if the clinical picture suggests thrombophilia (young + unprovoked VTE + family history), you must order specific thrombophilia tests — routine PT/APTT will not help you.

When a patient with Protein C deficiency presents with suspected VTE, the following investigations are needed to detect and characterise the thrombotic event:

Investigation	Indication / Finding	Interpretation
Compression ultrasonography (CUS) of lower limbs	First-line imaging for suspected DVT	Non-compressibility of a deep vein segment confirms DVT; can assess proximal (popliteal, femoral, iliac) vs distal (calf) veins
D-dimer	Risk stratification; sensitive but not specific ^[8]	High negative predictive value in low-risk patients → if negative in a low-probability patient, DVT/PE effectively ruled out ^[6]; if positive, must proceed to imaging
CT Pulmonary Angiography (CTPA)	Gold standard imaging for PE in haemodynamically stable patients	Directly visualises thrombus in pulmonary arteries; can detect RV dilatation (RV/LV ratio > 1 = poor prognosis)
ECG	Baseline; assess for right heart strain in PE	S1Q3T3 pattern, sinus tachycardia, RBBB, right axis deviation, T-wave inversion in V1–V4 ^[6]
CXR	Exclude other causes of dyspnoea; suggestive PE signs	Hampton hump (wedge-shaped opacity), Westermark sign (focal oligaemia), enlarged PA ^[6]; often normal or non-specific
ABG / SaO2	Assess severity of hypoxaemia in PE	Type 1 respiratory failure: ↓PaO2, normal/↓ PaCO2 with ↑ A-a gradient ^[6]; metabolic acidosis if massive PE with obstructive shock
Echocardiography (TTE)	In haemodynamically unstable patients with suspected massive PE	RV dilatation, RV hypokinesis, McConnell's sign (RV free wall akinesis with apical sparing); clot-in-transit may be visible; used when CTPA cannot be performed safely
Troponin / BNP	Prognostic in PE	Elevated troponin/BNP reflects RV myocardial strain → higher mortality risk ^[6]; does not diagnose PE
LDH, AST	Non-specific markers of tissue damage / right heart strain in PE	Right heart strain: ↑LDH, ↑AST ^[6]

Investigation	What It Excludes	Key Findings
Liver function tests (LFT)	Liver disease as cause of low Protein C	Three aspects of LFT: cellular integrity (ALT, AST), protein synthesis (albumin, PT), excretory function (bilirubin, ALP, GGT) ^[15] ^[16]; low albumin + prolonged PT → impaired hepatic synthetic function → Protein C likely reduced as part of global synthetic failure, not isolated deficiency
PT / INR	Warfarin effect; liver synthetic function; vitamin K deficiency	PT becomes abnormal when > 80% of liver synthetic capacity is lost in chronic liver disease ^[15]; Vitamin K assists in enzymatic formation of factors II, VII, IX, X, Protein C and S ^[15]
Factor V level	Distinguishes liver failure from vitamin K deficiency	Factor V is made by the liver but is NOT vitamin K–dependent. If Factor V is low → liver failure (global synthetic defect). If Factor V is normal but other vitamin K–dependent factors are low → vitamin K deficiency or warfarin effect
D-dimer, fibrinogen, platelet count	DIC	DIC: ↑PT, ↑APTT, ↓fibrinogen, ↑D-dimer, ↓platelets, schistocytes on PBS ^[2] ^[4]
Peripheral blood smear	DIC (schistocytes); other haematological conditions	Schistocytes (fragmented RBCs) = microangiopathic process (DIC, TTP, HUS)
Drug history	Warfarin, L-asparaginase, DOACs	No lab test replaces a thorough drug history; ask about anticoagulant use
Urinalysis + urine protein/creatinine ratio	Nephrotic syndrome (urinary loss of Protein C and antithrombin)	Heavy proteinuria ( > 3.5 g/day) + hypoalbuminaemia → nephrotic syndrome
Serum albumin	Nutritional status, liver disease, nephrotic syndrome	Low albumin with other low synthetic markers → liver failure; low albumin with heavy proteinuria → nephrotic syndrome

Clinical Scenario	Protein C Activity	Protein C Antigen	PT	APTT	Other Findings	Interpretation
Inherited Type I Protein C deficiency	↓	↓	Normal	Normal	Family history of VTE; low PC in relatives	Quantitative defect; AD inheritance
Inherited Type II Protein C deficiency	↓	Normal	Normal	Normal	Family history of VTE	Qualitative (dysfunctional) defect
Warfarin use	↓	Normal or ↓	↑	Normal or ↑	Patient is on warfarin; other VitK-dependent factors also low	False positive; retest after stopping warfarin ≥2 weeks ^[2]
Liver disease	↓	↓	↑	↑	Low albumin, low Factor V, elevated bilirubin/transaminases	Global hepatic synthetic failure; PC low as part of broader coagulopathy
Acute DIC	↓	↓	↑	↑	↓ Fibrinogen, ↑ D-dimer, ↓ platelets, schistocytes ^[2]	Consumption of all factors including natural anticoagulants
Acute thrombosis (without inherited deficiency)	Mildly ↓	Mildly ↓	Normal	Normal	Imaging-confirmed VTE	Consumption in the clot ^[1]; retest after ≥2–4 weeks
Vitamin K deficiency (cholestasis)	↓	Normal or ↓	↑	Normal or ↑	Jaundice, fat malabsorption; responds to parenteral vitamin K	Chronic cholestasis → fat malabsorption → impaired vitamin K absorption → reduced VitK-dependent factors ^[15]
Homozygous Protein C deficiency (neonate)	< 1% (undetectable)	< 1%	↑ (DIC)	↑ (DIC)	Purpura fulminans, widespread skin necrosis, DIC	Emergent replacement with Protein C concentrate

High Yield Summary — Diagnostics

Primary diagnostic test: Protein C activity (chromogenic assay) — this is the screening test. If normal, Protein C deficiency is excluded.
Typing: Add Protein C antigen. Type I = low antigen + low activity; Type II = normal antigen + low activity. ^[1]
PT and APTT are NORMAL in isolated Protein C deficiency — routine coagulation screening will miss it.
Never test during acute VTE or while on anticoagulants. Wait ≥2–4 weeks post-event; stop warfarin ≥2 weeks, DOAC ≥2 days. ^[2]
Always exclude acquired causes: warfarin, liver disease, DIC, vitamin K deficiency, sepsis, nephrotic syndrome, pregnancy.
Confirm with repeat testing on a separate occasion. Screen family members. Consider PROC gene sequencing for definitive diagnosis.
In Hong Kong Chinese patients, Factor V Leiden PCR and Prothrombin G20210A PCR can generally be omitted ^[11] — focus on Protein C, Protein S, Antithrombin, and APLS markers.
Thrombophilia screening tests: Protein C, Protein S, APCR, AT, Factor V Leiden PCR, Prothrombin G20210A mutation, APLS markers (anti-cardiolipin, lupus anticoagulant, anti-β2-GPI antibody). ^[2]

Active Recall - Protein C Deficiency: Diagnosis and Investigations

References

^[1] Senior notes: Block A - Leg swelling and chest pain: deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (Inherited thrombophilia sections on Protein C, Protein S, Antithrombin deficiency; Acquired deficiencies of natural anticoagulants) ^[2] Senior notes: Maksim Medicine Notes.pdf (Thrombophilia screening section, p.165; Clotting cascade interpretation, p.161) ^[4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (DIC investigations, case studies) ^[6] Senior notes: Ryan Ho Respiratory.pdf (PE investigations, D-dimer, CTPA, CXR, ECG, ABG) ^[8] Senior notes: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf (Coagulation cascade interpretation, mixing studies, D-dimer, lupus anticoagulant, DRVVT) ^[11] Senior notes: Adrian Lui Pediatrics Notes.pdf (Thrombophilia screening, Factor V Leiden not in Chinese, inherited thrombophilia table) ^[12] Senior notes: Ryan Ho Rheumatology.pdf (Antiphospholipid syndrome, Revised Sapporo criteria) ^[15] Senior notes: Block A - Abnormal bleeding after tooth extraction: bleeding tendency; thrombocytopenia.pdf (Laboratory tests of haemostasis, PT/APTT interpretation) ^[16] Senior notes: Block A - Introduction to GI/Hepatology investigations (LFT, Endoscopy).pdf (LFT parameters, liver synthetic function, PT, vitamin K–dependent factors)

Management Algorithm and Treatment Modalities

The management of Protein C deficiency operates on several distinct levels, each with its own clinical logic:

Acute management — treating an active VTE event in a patient with Protein C deficiency
Long-term anticoagulation — preventing recurrent VTE after the first event
Prophylactic management — preventing first or recurrent VTE in high-risk situations (surgery, pregnancy, immobilisation)
Special situations — warfarin-induced skin necrosis, homozygous neonatal purpura fulminans, perioperative management
Non-pharmacological measures — counselling, genetic counselling, family screening

Let's work through each systematically.

3. Acute VTE Management in Protein C Deficiency

When a patient with known or suspected Protein C deficiency presents with acute DVT or PE, the immediate treatment is identical to any acute VTE — start anticoagulation without delay. The underlying thrombophilia does not change the acute management algorithm; it changes the duration and long-term strategy.

Agent	Mechanism	Dose	Monitoring	Key Points
Low-Molecular-Weight Heparin (LMWH) e.g. enoxaparin	Enhances antithrombin's inhibition of Factor Xa (preferentially) and thrombin	Weight-based: e.g. enoxaparin 1 mg/kg SC BD or 1.5 mg/kg SC OD	Anti-Xa levels (if needed — e.g. renal impairment, extremes of body weight, pregnancy)	First-line for most patients; predictable pharmacokinetics; no routine monitoring needed in standard patients; contraindicated in severe renal impairment (CrCl < 30 mL/min) → use UFH instead
Unfractionated Heparin (UFH)	Enhances antithrombin's inhibition of both thrombin (IIa) and Factor Xa	IV bolus 80 U/kg then continuous infusion ~18 U/kg/hr; adjust to target APTT 60–80 seconds ^[18]	Monitor APTT (target 1.5–2.5× control) ^[18]	Preferred in: haemodynamically unstable PE (may need thrombolysis — short half-life allows quick cessation), severe renal impairment, perioperative setting (easily reversible with protamine)
Fondaparinux	Synthetic pentasaccharide → selective Factor Xa inhibitor via antithrombin	Weight-based SC OD: < 50 kg: 5 mg; 50–100 kg: 7.5 mg; > 100 kg: 10 mg	No routine monitoring	Alternative to LMWH; used especially if history of HIT (no cross-reactivity with anti-PF4 antibodies); contraindicated in severe renal impairment

Heparin works by enhancing antithrombin activity. This is why antithrombin deficiency results in VTE often resistant to normal doses of heparin ^[11] — but in Protein C deficiency, heparin responsiveness is normal because antithrombin is intact.

Why Parenteral Anticoagulation First?

The logic is simple: you need immediate anticoagulant effect. Oral agents (warfarin) take days to reach therapeutic effect. LMWH/UFH work within hours. In Protein C deficiency specifically, parenteral heparin also serves as a mandatory bridge when transitioning to warfarin — to prevent warfarin-induced skin necrosis (see below).

4. Transition to Long-Term Oral Anticoagulation

After the acute phase (typically ≥5 days of parenteral anticoagulation), patients are transitioned to long-term oral anticoagulation. There are two main options:

DOACs have become the preferred first-line agents for VTE treatment in most patients, including those with inherited thrombophilia (Protein C deficiency).

DOAC	Mechanism	Dose for VTE Treatment	Advantages	Considerations
Rivaroxaban ("riva" = river, "xa" = Factor Xa, "ban" = inhibitor)	Direct Factor Xa inhibitor	15 mg BD × 3 weeks, then 20 mg OD	No bridging needed — can start directly (has rapid onset); fixed dosing; no routine INR monitoring	Take with food (↑ absorption); dose-adjust in renal impairment
Apixaban	Direct Factor Xa inhibitor	10 mg BD × 7 days, then 5 mg BD	No bridging needed; lowest bleeding risk among DOACs; twice-daily dosing	Dose-adjust for age ≥ 80, weight ≤ 60 kg, or Cr ≥ 133 μmol/L (if ≥2 of 3 criteria → 2.5 mg BD)
Edoxaban	Direct Factor Xa inhibitor	60 mg OD (after ≥5 days parenteral anticoagulation)	Once-daily; good renal clearance profile	Requires ≥5 days of initial heparin (unlike rivaroxaban/apixaban)
Dabigatran ("dabiga" = thrombin, "tran" = inhibitor)	Direct thrombin (IIa) inhibitor	150 mg BD (after ≥5 days parenteral anticoagulation)	Once reversible with specific antidote (idarucizumab)	Requires ≥5 days of initial heparin; highest GI bleeding risk; largely renally excreted → avoid if CrCl < 30

Key advantages of DOACs over warfarin in Protein C deficiency:

No risk of warfarin-induced skin necrosis — DOACs do not affect vitamin K–dependent protein synthesis, so they do not create the transient hypercoagulable state that warfarin does
Fixed dosing, no routine INR monitoring, fewer drug–food interactions
Rivaroxaban and apixaban can be started without heparin bridging (they have rapid onset of action with a "lead-in" high-dose phase)

Contraindications/limitations of DOACs:

Contraindication	Rationale
Severe renal impairment (CrCl < 15–30 mL/min, varies by agent)	DOACs are renally excreted to varying degrees; accumulation → bleeding risk
Mechanical heart valves	DOACs are contraindicated — warfarin remains standard
APLS (triple-positive)	Trial data (TRAPS trial) showed rivaroxaban was inferior to warfarin in triple-positive APLS → warfarin preferred ^[17]
Pregnancy and breastfeeding	DOACs cross the placenta and are present in breast milk; insufficient safety data → use LMWH
Significant hepatic impairment (Child-Pugh B/C)	Impaired metabolism; some agents contraindicated
Active GI bleeding / high GI bleeding risk	Some DOACs (especially dabigatran, rivaroxaban) have higher GI bleeding rates than warfarin

Warfarin is a vitamin K antagonist → reduces factors II, VII, IX, X ^[21]

Warfarin remains a valid option for long-term anticoagulation in Protein C deficiency, but requires special precautions due to the risk of warfarin-induced skin necrosis.

Parameter	Detail
Mechanism	Inhibits vitamin K epoxide reductase (VKORC1) → impairs γ-carboxylation of vitamin K–dependent factors (II, VII, IX, X) AND Protein C and Protein S
Target INR	2.0–3.0 for standard VTE treatment
Monitoring	INR monitoring; time in therapeutic range (TTR) correlates with reduced stroke risk and improved survival ^[21]
Onset	Slow (3–5 days to reach therapeutic INR) — this is why bridging with heparin is mandatory

Warfarin Initiation in Protein C Deficiency — CRITICAL RULE

Warfarin-induced skin necrosis occurs in the first 3–5 days of warfarin therapy due to rapid depletion of Protein C (short half-life ~6–8 hours) while procoagulant factors remain elevated → transient hypercoagulable state → microvascular thrombosis → haemorrhagic skin necrosis. ^[2] ^[11]

Mandatory precautions when starting warfarin in Protein C deficiency:

ALWAYS bridge with heparin (LMWH or UFH) when starting warfarin — never start warfarin alone
Start warfarin at a LOW dose (e.g. 2–5 mg/day; avoid loading doses) to minimise the rate of Protein C depletion
Overlap heparin and warfarin for ≥5 days AND until INR is 2.0–3.0 for at least 2 consecutive days before stopping heparin
If warfarin-induced skin necrosis occurs: stop warfarin immediately, give IV heparin (full anticoagulation), consider Protein C concentrate replacement, and do not re-challenge with warfarin — switch to a DOAC

Bridging with LMWH indications include known hypercoagulability e.g. Protein C/S deficiency ^[22]

Factor	Favours DOAC	Favours Warfarin
Risk of warfarin-induced skin necrosis	✓ (DOACs do not cause this)	✗ (risk present)
Monitoring burden	✓ (no routine INR)	✗ (regular INR needed)
Drug interactions	✓ (fewer)	✗ (many — vitamin K intake, CYP interactions)
Pharmacogenomic variability	✓ (less variable)	✗ (30% of warfarin response attributable to genetic variation in VKORC1, CYP2C9) ^[21]
Mechanical heart valve	✗ (contraindicated)	✓ (standard of care)
APLS (triple-positive)	✗ (inferior per TRAPS trial)	✓ (preferred)
Pregnancy	✗ (contraindicated)	✗ (teratogenic — use LMWH)
Severe renal impairment	✗ (most DOACs contraindicated)	✓ (not renally excreted)
Reversal agent availability	Variable (idarucizumab for dabigatran; andexanet alfa for Xa inhibitors — limited availability)	✓ (Vitamin K + FFP/PCC widely available)
Cost	✗ (more expensive)	✓ (cheaper)

This is a crucial clinical decision point. The duration depends on whether the VTE was provoked or unprovoked, and the severity of the thrombophilia.

Scenario	Recommended Duration	Rationale
First unprovoked VTE + heterozygous Protein C deficiency	Indefinite anticoagulation ^[17] ^[11]	Lifelong hypercoagulable state → high recurrence risk (~50% in 10 years without anticoagulation); benefits of continued anticoagulation generally outweigh bleeding risks
First provoked VTE + heterozygous Protein C deficiency (e.g. post-surgery, OCP-related)	At least 3–6 months; consider extended/indefinite depending on individual risk assessment	The provoking factor has been removed, but the underlying thrombophilia persists → decision must be individualised
Recurrent VTE + Protein C deficiency	Indefinite anticoagulation	Recurrence confirms high thrombotic risk
Homozygous Protein C deficiency	Lifelong anticoagulation (started in neonatal period after initial Protein C concentrate replacement)	Near-zero endogenous Protein C → extreme thrombotic risk without anticoagulation
Asymptomatic heterozygous carrier (never had VTE)	No routine anticoagulation	Risk of VTE is increased but not certain; anticoagulation carries bleeding risk; only provide prophylaxis in high-risk situations

Anticoagulation in VTE → should continue indefinitely for Protein C deficiency ^[17]. For Protein S deficiency, individualise the decision for indefinite anticoagulation ^[17].

6. Prophylactic Management (Asymptomatic Carriers and High-Risk Situations)

Prophylactic anticoagulation in pregnancy, surgery, or post-VTE is a key principle for Protein C deficiency ^[17] ^[11].

Situation	Management
Asymptomatic carrier undergoing surgery	Perioperative LMWH prophylaxis (e.g. enoxaparin 40 mg SC OD); graduated compression stockings; early mobilisation
Patient on warfarin undergoing elective surgery	Stop warfarin 5 days before operation (if INR 2–3) ^[22]; check INR the day before — aim INR < 1.5 for most operations ^[22]; bridge with SC LMWH when INR becomes subtherapeutic → discontinue LMWH 12 hours before operation ^[22]
Post-operative restart	Low bleeding risk: restart warfarin at evening of procedure / 12–24 hours after operation ^[22]; High bleeding risk: restart at least 48 hours after operation ^[22]; consider post-op low-dose LMWH if high risk (takes 5–10 days for warfarin to attain anticoagulant effect) ^[22]
Emergency surgery on warfarin	Stop warfarin; reverse with IV vitamin K ± PCC (prothrombin complex concentrate) or FFP if urgent ^[22]

Pregnancy is a uniquely challenging situation because:

Pregnancy itself is a hypercoagulable state (↑ fibrinogen, ↑ Factor VII, VIII, vWF; ↓ Protein S; ↓ fibrinolysis; venous stasis from uterine compression) ^[17]
Warfarin crosses the placenta → risk of fetal ICH and teratogenicity ^[17]
DOACs are contraindicated in pregnancy (cross placenta, insufficient safety data)
LMWH is the only safe anticoagulant in pregnancy

Trimester	Management
Pre-conception	Counsel about VTE risk; if on warfarin, plan switch to LMWH before conception or as soon as pregnancy confirmed
1st trimester	Switch to LMWH ^[17] — warfarin is teratogenic (nasal hypoplasia, stippled epiphyses, CNS abnormalities if exposed weeks 6–12)
2nd trimester	Continue LMWH prophylactic or therapeutic dose (depending on VTE history)
3rd trimester	Continue LMWH; admit 2–3 weeks prior to expected delivery for UFH (shorter half-life, reversible with protamine → safer for delivery) ^[22]
Delivery	Stop LMWH ≥24 hours before planned delivery (or switch to UFH and stop 4–6 hours before); allows epidural/spinal anaesthesia
Post-partum	Cover up to 6 weeks post-partum (highest risk period as blood returns from uterus) ^[17]; can restart warfarin post-partum (safe in breastfeeding — warfarin does not cross into breast milk in significant amounts)

Situation	Management
Prolonged immobilisation (hospitalisation, plaster cast, bed rest)	LMWH prophylaxis for the duration of immobilisation
Long-haul travel ( > 4 hours)	Graduated compression stockings; adequate hydration; mobilisation during flight; consider single-dose LMWH in very high-risk individuals
OCP / HRT avoidance	Oestrogen-containing contraceptives increase VTE risk 2–4× ^[6] and are synergistic with inherited thrombophilia → absolutely contraindicated in Protein C deficiency; use progesterone-only contraception or non-hormonal methods
Smoking cessation	Smoking is an independent VTE risk factor; counsel cessation
Weight management	Obesity increases VTE risk; encourage healthy BMI

7. Management of Special Situations

This is the feared complication that specifically points to Protein C (or Protein S) deficiency.

Step	Action	Rationale
1. Recognise	Painful ecchymotic patches (breasts, buttocks, thighs, abdomen) → rapidly progressing to haemorrhagic necrosis, typically days 3–5 of warfarin therapy	Rapid Protein C depletion → transient hypercoagulable state → microvascular skin thrombosis
2. Stop warfarin immediately	Remove the cause of ongoing Protein C depletion
3. Start full-dose heparin (UFH or LMWH)	Provide anticoagulation via antithrombin pathway (independent of Protein C)
4. Protein C concentrate	Replaces the deficient protein directly; restores the Protein C anticoagulant pathway	Ceprotin® (human Protein C concentrate) — derived from pooled human plasma; dosed to achieve Protein C activity > 100% initially
5. Fresh frozen plasma (FFP)	Contains all coagulation factors including Protein C; alternative if Protein C concentrate not available	FFP indications include immediate reversal of warfarin overdose with bleeding ^[23]; provides Protein C along with other factors
6. Vitamin K	Reverses warfarin effect; restores vitamin K–dependent factor synthesis (including Protein C)	Oral or IV vitamin K 5–10 mg
7. Wound care	Surgical debridement of necrotic skin if needed; skin grafting for extensive lesions
8. Switch to DOAC	For long-term anticoagulation — do NOT re-challenge with warfarin	DOACs do not affect Protein C levels

This is a haematological emergency in neonates.

Step	Action
1. Immediate Protein C replacement	Protein C concentrate (Ceprotin®): initial bolus 100–120 IU/kg IV; then 60–80 IU/kg every 6–12 hours to maintain Protein C activity > 25% (acute phase); long-term maintenance: 45–60 IU/kg every 12 hours, adjusted by trough levels
2. If Protein C concentrate unavailable	Fresh frozen plasma (FFP) 10–20 mL/kg every 6–12 hours — contains Protein C but in much lower concentration → risk of volume overload ^[23]
3. Heparin	Start UFH once Protein C is replaced → prevents further microthrombosis
4. Transition to long-term anticoagulation	Once stabilised → lifelong warfarin (with careful initiation under Protein C concentrate cover) OR DOAC (limited paediatric data, but increasingly used); some children may require long-term Protein C concentrate replacement
5. Supportive care	NICU admission; wound care for necrotic lesions; skin grafting as needed; DIC management (platelet, cryoprecipitate transfusion if needed)
6. Genetic counselling	Both parents are obligate heterozygous carriers; counsel about future pregnancies; prenatal diagnosis available

Patients on long-term anticoagulation for Protein C deficiency may experience bleeding complications. Know the reversal agents:

Anticoagulant	Reversal Agent	Mechanism
Warfarin	Vitamin K (phytomenadione) 5–10 mg IV/PO; PCC (4-factor prothrombin complex concentrate) for life-threatening bleeding; FFP if PCC unavailable ^[22] ^[23]	Vitamin K restores γ-carboxylation; PCC provides concentrated vitamin K–dependent factors (II, VII, IX, X); FFP provides all factors
UFH	Protamine sulphate 1 mg per 100 U heparin (max 50 mg)	Binds heparin electrostatically, neutralising its effect
LMWH	Protamine (partial reversal only — ~60% neutralisation of LMWH anti-Xa activity)	Less effective than for UFH because protamine cannot neutralise the shorter anti-Xa chains
Dabigatran	Idarucizumab (Praxbind®) 5 g IV	Monoclonal antibody fragment that binds dabigatran with 350× higher affinity than thrombin
Rivaroxaban / Apixaban	Andexanet alfa (Andexxa®) — limited availability; alternatively 4-factor PCC 50 IU/kg as empirical treatment	Recombinant modified Factor Xa that acts as a decoy, sequestering the Xa inhibitor

Treatment	Indication	Contraindications / Cautions
LMWH (e.g. enoxaparin)	Acute VTE (initial treatment); thromboprophylaxis in surgery, pregnancy, immobilisation; bridging for warfarin	Severe renal impairment (CrCl < 30); HIT (use fondaparinux instead); active uncontrolled bleeding
UFH	Acute VTE (especially if haemodynamically unstable / renal failure); perioperative; when rapid reversibility needed	HIT; active bleeding; relative: thrombocytopenia
Fondaparinux	Alternative to LMWH; especially if HIT history	Severe renal impairment (CrCl < 20); weight < 50 kg (increased bleeding risk)
Warfarin	Long-term VTE treatment/prophylaxis; mechanical heart valves; APLS	MUST bridge with heparin — never start alone in Protein C deficiency; pregnancy (teratogenic); severe liver disease; active bleeding
DOACs (rivaroxaban, apixaban, edoxaban, dabigatran)	Long-term VTE treatment — now preferred first-line over warfarin in most cases; no warfarin-induced skin necrosis risk	Severe renal impairment; mechanical heart valves; triple-positive APLS; pregnancy; significant hepatic impairment
Protein C concentrate (Ceprotin®)	Homozygous neonatal purpura fulminans; warfarin-induced skin necrosis; perioperative cover in severe deficiency	None absolute; cost and availability are main limitations
FFP	Alternative source of Protein C; DIC; warfarin reversal; massive bleeding	Volume overload; risk of transfusion reactions; ABO compatibility required ^[23]
Thrombolysis (rtPA)	Massive PE with haemodynamic instability	Absolute: haemorrhagic stroke, active bleeding, suspected aortic dissection, intracranial neoplasm ^[20]; Relative: severe HTN, recent surgery, pregnancy ^[20]
Graduated compression stockings	DVT prophylaxis (adjunct); post-thrombotic syndrome prevention	Peripheral arterial disease (can worsen ischaemia)
IVC filter	If anticoagulation absolutely contraindicated AND recurrent/life-threatening PE	Thrombosis of filter itself; should be temporary and retrieved when anticoagulation can resume
OCP avoidance	All women with Protein C deficiency	Oestrogen-containing contraceptives absolutely contraindicated; use progesterone-only or non-hormonal methods

Measure	Detail
Patient education	Explain the lifelong nature of the condition; signs and symptoms of VTE (leg swelling, chest pain, dyspnoea); when to seek emergency care; importance of medication adherence
Medical alert identification	Wear a medical alert bracelet/card stating Protein C deficiency and current anticoagulant therapy → essential for emergency situations
Genetic counselling	Autosomal dominant inheritance ^[1] → 50% chance of passing to each child; screen first-degree relatives; prenatal diagnosis available for severe (homozygous) cases
Family screening	Offer Protein C testing to all first-degree relatives; asymptomatic carriers should receive prophylactic counselling
Lifestyle modification	Avoid prolonged immobilisation; stay hydrated; maintain healthy weight; avoid smoking; avoid oestrogen-containing contraceptives/HRT
Pre-conception counselling	Plan pregnancy with haematology input; switch from warfarin/DOAC to LMWH before conception; discuss thromboprophylaxis plan throughout pregnancy and post-partum

High Yield Summary — Management

Acute VTE: Start parenteral anticoagulation (LMWH or UFH) immediately. Massive PE → thrombolysis if no contraindications; ICU care.
Long-term anticoagulation: DOACs are now preferred first-line (no risk of warfarin-induced skin necrosis; no INR monitoring). Warfarin remains an option but MUST be bridged with heparin and started at low dose.
Warfarin in Protein C deficiency → ALWAYS bridge with heparin; NEVER start warfarin alone ^[22]. Warfarin-induced skin necrosis occurs days 3–5 due to rapid Protein C depletion.
Duration: anticoagulation should continue indefinitely after first unprovoked VTE ^[17]. Asymptomatic carriers do not need routine anticoagulation.
Prophylactic anticoagulation in pregnancy, surgery, or post-VTE ^[17] ^[11]. Pregnancy: use LMWH throughout (warfarin teratogenic, DOACs contraindicated); cover up to 6 weeks post-partum.
Homozygous neonatal purpura fulminans: Protein C concentrate (Ceprotin®) is life-saving; FFP as alternative; followed by lifelong anticoagulation.
Oestrogen-containing contraceptives are absolutely contraindicated in Protein C deficiency (synergistic VTE risk).
Family screening and genetic counselling are integral parts of management.

Active Recall - Protein C Deficiency: Management

References

^[1] Senior notes: Block A - Leg swelling and chest pain: deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (Inherited thrombophilia sections on Protein C, Protein S, Antithrombin deficiency; Acquired deficiencies) ^[2] Senior notes: Maksim Medicine Notes.pdf (Thrombophilia screening, DIC, purpura fulminans, p.165) ^[6] Senior notes: Ryan Ho Respiratory.pdf (PE risk factors, CTPA, V/Q scan, management, p.134–136) ^[11] Senior notes: Adrian Lui Pediatrics Notes.pdf (Thrombophilia screening, inherited thrombophilia treatment table, p.397) ^[17] Senior notes: Ryan Ho Haemtology.pdf (Thrombophilia screening, inherited thrombophilia management table, VTE anticoagulation management, p.132–135) ^[18] Senior notes: Maksim Surgery Notes.pdf (Heparin infusion, APTT monitoring, acute limb ischaemia management, p.169) ^[19] Senior notes: Block A - Chest Pain - Department of Medicine.pdf (Unstable PE management, TTE, heparin, oxygen therapy) ^[20] Senior notes: Ryan Ho Cardiology.pdf (Thrombolysis contraindications table, p.138) ^[21] Senior notes: Introduction to Clinical pharmacology (I) (Pharmaco-Genomics, Precision Medicine).pdf (Warfarin pharmacogenomics, VKORC1, CYP variability) ^[22] Senior notes: Maksim Surgery Notes.pdf (Perioperative warfarin management, bridging with LMWH, indications, p.26) ^[23] Senior notes: Ryan Ho Haemtology.pdf (FFP indications, PCC, cryoprecipitate, blood product transfusion, p.144)

Complications of Protein C Deficiency

The complications of Protein C deficiency can be organised into three categories:

Direct complications — the thrombotic events that result from the hypercoagulable state itself
Treatment-related complications — adverse effects of the anticoagulant therapy used to manage the condition
Psychosocial and reproductive complications — the lifelong burden of a hereditary thrombophilia

Each complication is explained from first principles, linking back to the underlying pathophysiology.

1. Direct Thrombotic Complications

These are the complications of the disease itself — they stem from the fundamental defect: inadequate inactivation of Factor Va and Factor VIIIa → excessive thrombin generation → venous (and rarely arterial) thrombosis.

Feature	Detail
Why it occurs	Protein C deficiency → persistent Factor Va/VIIIa → excess thrombin → excess fibrin → venous thrombus formation, especially in areas of slow flow (lower limbs). The higher the level of thrombosis, the greater the risk of embolisation ^[14]
Typical presentation	Unilateral leg swelling, pain, warmth, erythema; proximal DVT (popliteal, femoral, iliac) is more clinically significant than distal (calf) DVT
Recurrence risk	Without anticoagulation, heterozygous Protein C–deficient patients have a lifetime recurrence rate of ~50% over 10 years. The risk is cumulative and lifelong — which is why anticoagulation should continue indefinitely ^[17]
Unusual-site DVT	Protein C deficiency predisposes to thrombosis in unusual venous sites: cerebral venous sinus thrombosis, portal vein thrombosis, mesenteric vein thrombosis, renal vein thrombosis. These are important because they are often missed initially and carry high morbidity

Feature	Detail
Why it occurs	DVT (especially proximal) → thrombus dislodges and embolises via IVC → right heart → pulmonary arteries → mechanical obstruction of pulmonary vascular bed
Pathophysiology of death from PE	Patients with PE usually die from right heart failure (cardiogenic shock) rather than hypoxaemia ^[4]. A large PE acutely increases RV afterload → RV dilatation and failure → ↓ cardiac output → obstructive shock
Clinical spectrum	Ranges from small subsegmental PE (incidental finding, minimal symptoms) to massive PE (haemodynamic collapse, death). Protein C deficiency patients may have recurrent small PEs that gradually lead to chronic thromboembolic pulmonary hypertension

Feature	Detail
Why it occurs	Recurrent PEs that do not fully resolve → organised thrombus in pulmonary vasculature → chronic mechanical obstruction + vascular remodelling → progressive ↑ pulmonary arterial pressure
Consequence	Progressive RV failure → exercise intolerance, dyspnoea, peripheral oedema, hepatic congestion, syncope
Clinical relevance	CTEPH is a potentially treatable form of pulmonary hypertension (via pulmonary endarterectomy or balloon pulmonary angioplasty). It must be considered in any Protein C–deficient patient with progressive exertional dyspnoea after prior PE

Feature	Detail
Why it occurs	After DVT resolves, the thrombus damages the venous valves of the deep leg veins → chronic venous valve incompetence → blood refluxes downwards → chronic venous hypertension in the distal leg
Prevalence	Develops in 20–50% of patients after proximal DVT, typically within 1–2 years
Clinical features	Chronic leg oedema, heaviness, aching, skin hyperpigmentation (haemosiderin deposition from extravasated RBC breakdown → brown discolouration around medial malleolus), lipodermatosclerosis (fibrosis and induration of subcutaneous tissue), venous eczema, and ultimately venous ulceration (classically around the medial malleolus — the "gaiter zone")
Pathophysiology of venous ulcer	Chronic venous hypertension → capillary dilatation → fibrin cuff deposition around capillaries → impaired O₂/nutrient exchange → tissue ischaemia → ulceration
Prevention and management	Graduated compression stockings (though recent evidence from the SOX trial questions their efficacy in PTS prevention); adequate initial anticoagulation to reduce residual vein thrombosis; leg elevation; wound care for established ulcers

Feature	Detail
Why it occurs	Hypercoagulable state → thrombosis of cerebral dural sinuses (e.g. superior sagittal sinus, transverse sinus) → impaired venous drainage of the brain
Consequences	Raised intracranial pressure → headache, papilloedema, visual disturbance; venous infarction → focal neurological deficits, seizures; haemorrhagic transformation of venous infarcts; coma/death if untreated
Clinical relevance	Should be suspected in any young patient with unusual headache + papilloedema ± focal neurological signs, especially if they have a known thrombophilia or additional risk factors (pregnancy, OCP, dehydration)

Site	Consequence
Portal vein thrombosis	Pre-hepatic portal hypertension → increased variceal bleeding, increased ascites ^[24]; may be clinically silent initially and detected incidentally on surveillance ultrasound; chronic → cavernous transformation (development of collaterals) ^[24]
Mesenteric vein thrombosis	Bowel ischaemia → acute abdomen, bloody diarrhoea; can progress to bowel infarction → peritonitis, sepsis, death
Hepatic vein thrombosis (Budd-Chiari syndrome)	Hepatic venous outflow obstruction → hepatic congestion → ascites, hepatomegaly, abdominal pain; acute form → fulminant liver failure
Renal vein thrombosis	Flank pain, haematuria, acute kidney injury; heavy proteinuria (chicken-and-egg with nephrotic syndrome — nephrotic syndrome → loss of antithrombin → thrombosis; renal vein thrombosis → heavy proteinuria → nephrotic syndrome ^[1])

This is both a complication of the disease AND a complication of treatment — it occurs specifically because of the interaction between Protein C deficiency and warfarin therapy.

Feature	Detail
Why it occurs	Warfarin depletes Protein C rapidly (half-life ~6–8 hours) before procoagulant factors (II, X) drop → transient hypercoagulable state → microvascular thrombosis in skin/subcutaneous fat ^[2]. In patients who already have low Protein C (heterozygous deficiency), this effect is severely exaggerated
Timing	Days 3–5 of warfarin initiation (or dose escalation)
Affected sites	Areas rich in subcutaneous fat: breasts, buttocks, thighs, abdomen
Clinical appearance	Initial painful erythema → ecchymotic patches → rapidly progressing to full-thickness haemorrhagic necrosis with sharply demarcated borders and central black eschar
Management	Stop warfarin immediately; full-dose heparin; Protein C concentrate; vitamin K; wound debridement/skin grafting; switch to DOAC for long-term anticoagulation
Prevention	Always bridge with heparin when starting warfarin; start at low dose; overlap for ≥5 days until therapeutic INR achieved ^[22]

Warfarin-induced skin necrosis is associated with Protein C/S deficiency — this is a classic thrombophilia screening indication ^[2].

Feature	Detail
Why it occurs	Near-zero Protein C activity → completely unopposed thrombin generation from birth → widespread microvascular thrombosis → DIC
Clinical presentation	Within hours to days of birth: widespread ecchymotic skin lesions rapidly coalescing into large areas of haemorrhagic necrosis; DIC (oozing from puncture sites, mucosal bleeding); organ damage (cerebral, renal, ophthalmological)
Mortality	Fatal without immediate treatment
Long-term sequelae	Even with treatment, survivors may have: skin scarring requiring grafting; limb amputation (if extensive extremity necrosis); neurological deficits (from cerebral thrombosis); visual impairment (retinal vessel thrombosis)

Purpura fulminans is due to Protein C deficiency ^[2] — this can occur in homozygous inherited deficiency OR in acquired severe Protein C deficiency (e.g. DIC from meningococcal sepsis).

Feature	Detail
Why it occurs	Placental microvascular thrombosis → placental insufficiency → intrauterine growth restriction, stillbirth, recurrent miscarriage
Association strength	The association between Protein C deficiency and pregnancy loss is weaker than that for APLS, but some studies show a 2–3× increased risk of late pregnancy loss
Clinical relevance	All women with Protein C deficiency should receive thromboprophylaxis during pregnancy (LMWH) and post-partum — this also reduces placental thrombosis risk

Feature	Detail
Why it occurs	Although Protein C deficiency predominantly causes venous thrombosis, rare cases of ischaemic stroke and arterial thromboembolism have been reported, especially in severe deficiency, compound heterozygosity, or when combined with other prothrombotic risk factors
Mechanisms	Hypercoagulability contributing to stroke via cerebrovascular blood flow abnormality: protein C/S deficiency ^[7]; paradoxical embolism through patent foramen ovale; in situ arterial thrombosis (very rare)

Patients with Protein C deficiency require long-term (usually indefinite) anticoagulation. This exposes them to the complications of anticoagulant therapy.

Type	Mechanism	Risk Factors	Management
Major bleeding (GI haemorrhage, intracranial haemorrhage, retroperitoneal bleed)	Anticoagulation reduces the body's ability to form clots → any vessel injury results in prolonged/excessive bleeding	Elderly age, concurrent antiplatelet use, renal impairment, excessive anticoagulation (INR > 4 for warfarin), falls risk, prior GI bleeding	Stop anticoagulant; reversal agent (vitamin K + PCC for warfarin; idarucizumab for dabigatran; andexanet alfa or PCC for Xa inhibitors); blood product support (FFP, platelets, RBC as needed); identify and treat bleeding source
Minor bleeding (epistaxis, gum bleeding, easy bruising, menorrhagia)	Same mechanism; lower clinical consequence	As above	Local measures; dose adjustment; consider switching anticoagulant
Warfarin over-anticoagulation (INR > 4 without bleeding)	Excessive warfarin dose or drug interaction	CYP2C9 and VKORC1 polymorphisms affect warfarin sensitivity ^[21]; concurrent CYP inhibitors (amiodarone, azole antifungals, macrolides); hepatic impairment; vitamin K–poor diet	Withhold warfarin 1–2 doses; low-dose oral vitamin K (1–2.5 mg) if INR > 5; recheck INR; resume at lower dose

Balancing Act

The central challenge of managing Protein C deficiency is balancing thrombotic risk (from the underlying deficiency) against bleeding risk (from the anticoagulation used to treat it). This requires regular reassessment, patient education about warning signs of both thrombosis AND bleeding, and careful dose titration.

Warfarin has a notoriously narrow therapeutic index and is subject to numerous drug and dietary interactions — this is especially relevant for patients on lifelong therapy.

Interaction Type	Examples	Effect
CYP inhibitors (↑ warfarin effect → ↑ INR → bleeding risk)	Amiodarone, azole antifungals (fluconazole, voriconazole), macrolides (erythromycin, clarithromycin), metronidazole, SSRIs	Reduced warfarin metabolism → accumulation → supra-therapeutic INR
CYP inducers (↓ warfarin effect → ↓ INR → thrombosis risk)	Rifampicin, carbamazepine, phenytoin, St John's Wort	Increased warfarin metabolism → subtherapeutic INR → VTE recurrence
Dietary vitamin K	Green leafy vegetables (kale, spinach, broccoli)	High vitamin K intake antagonises warfarin → ↓ INR; sudden dietary change can destabilise control
Pharmacogenomic variation	VKORC1 and CYP2C9 polymorphisms → 30% of warfarin dose variability ^[21]	Some patients are exquisitely sensitive or resistant to warfarin

DOACs have fewer (but not zero) drug interactions — notable interactions include strong CYP3A4/P-glycoprotein inhibitors and inducers.

Feature	Detail
Why it matters	Patients with Protein C deficiency receiving heparin (LMWH or UFH) during acute VTE treatment or bridging are at risk of developing HIT Type II
Mechanism	Autoantibodies against PF4-heparin complex → platelet activation → paradoxical arterial and venous thrombosis + thrombocytopenia
Diagnosis	4T score; anti-PF4/heparin antibodies; platelet count drop > 50% typically 5–10 days after heparin initiation
Management	Stop all heparin immediately; start non-heparin anticoagulant (argatroban or fondaparinux); do NOT give warfarin until platelets recover (warfarin in HIT can precipitate venous limb gangrene — same mechanism as warfarin-induced skin necrosis: rapid Protein C depletion in a procoagulant state); bridge to warfarin or DOAC once platelets > 150

Feature	Detail
Why it occurs	Long-term UFH (> 3 months) inhibits osteoblast function and promotes osteoclast activity → reduced bone mineral density
Clinical relevance	Mainly relevant for pregnant patients with Protein C deficiency on prolonged LMWH (lower risk than UFH but still present); or patients who cannot take oral anticoagulants
Prevention	Use LMWH over UFH when possible (lower osteoporosis risk); transition to oral anticoagulant post-partum; ensure adequate calcium and vitamin D supplementation

3. Psychosocial and Reproductive Complications

Feature	Detail
Chronic disease anxiety	Lifelong diagnosis with the knowledge of being at constant thrombotic risk → anxiety about recurrent events, especially in young patients
Medication burden	Indefinite anticoagulation → daily medication, periodic monitoring (if on warfarin), dietary restrictions (vitamin K–stable diet on warfarin), activity restrictions (contact sports)
Impact on career/lifestyle	Occupations with high injury risk may be inadvisable; travel requires planning (medication supply, compression stockings, awareness of healthcare access)

Feature	Detail
OCP contraindication	Oestrogen-containing contraceptives increase VTE risk 2–4× ^[6] and are synergistically harmful in Protein C deficiency → absolutely contraindicated; must use progesterone-only or non-hormonal methods
HRT contraindication	Same principle — oestrogen-containing HRT increases VTE risk; contraindicated or requires very careful risk assessment
Pregnancy risk	Increased VTE risk throughout pregnancy and especially post-partum; requires planned thromboprophylaxis with LMWH throughout pregnancy and for 6 weeks post-partum; warfarin crosses the placenta → teratogenic ^[17]; DOACs contraindicated
Genetic transmission	Autosomal dominant inheritance ^[1] → 50% chance of passing the mutation to each child; requires genetic counselling before family planning; prenatal diagnosis possible for severe (homozygous) disease if both parents are carriers
Recurrent miscarriage	Placental microvascular thrombosis may contribute to pregnancy loss (though the association is weaker than for APLS)

4. Complications Unique to Specific Clinical Contexts

Protein C deficiency rarely exists in isolation — it commonly interacts with acquired risk factors to precipitate VTE:

Acquired Risk Factor	Interaction with Protein C Deficiency
Surgery/immobilisation	Stasis + hypercoagulability → synergistic VTE risk; perioperative thromboprophylaxis is mandatory
Pregnancy	Physiological ↑ clotting factors + ↓ Protein S + venous stasis + underlying Protein C deficiency → markedly ↑ VTE risk
OCP/HRT	Oestrogens increase clotting factor synthesis ^[14] + underlying deficiency → multiplicative risk
Malignancy	Tumour-derived tissue factor + underlying deficiency → very high VTE risk
Nephrotic syndrome	Urinary loss of antithrombin ^[24] + existing Protein C deficiency → compound anticoagulant deficiency → extreme thrombotic risk

Complication	Mechanism	Key Clinical Points
DVT	Excess thrombin → fibrin-rich venous thrombus	Most common presentation; proximal > distal; recurrent without anticoagulation
PE	DVT embolism to pulmonary arteries	Death from RV failure, not hypoxaemia ^[4]; can be massive and fatal
CTEPH	Organised thrombus in pulmonary vasculature	Progressive dyspnoea after PE; treatable (pulmonary endarterectomy)
Post-thrombotic syndrome	Valve damage → chronic venous insufficiency	Oedema, pigmentation, lipodermatosclerosis, venous ulcers
CVST	Cerebral dural sinus thrombosis	Headache, papilloedema, seizures, focal deficits
Splanchnic vein thrombosis	Portal/mesenteric/hepatic/renal vein thrombosis	Variceal bleeding, bowel ischaemia, Budd-Chiari, renal vein thrombosis
Warfarin-induced skin necrosis	Rapid Protein C depletion on warfarin	Days 3–5; fatty areas; bridge with heparin to prevent
Neonatal purpura fulminans	Near-zero Protein C (homozygous) → widespread microvascular thrombosis	Haemorrhagic skin necrosis, DIC; fatal without Protein C concentrate
Recurrent pregnancy loss	Placental microthrombosis	LMWH prophylaxis in pregnancy
Anticoagulant-related bleeding	Treatment complication	Balance thrombotic vs bleeding risk; know reversal agents
HIT	Heparin treatment complication	Stop heparin; non-heparin anticoagulant
DIC	Extreme Protein C deficiency → unchecked thrombin	Multi-organ dysfunction

High Yield Summary — Complications

DVT and PE are the most common complications. Patients die from RV failure in PE, not hypoxaemia ^[4]. The higher the level of venous thrombosis, the greater the risk of embolisation ^[14].
Post-thrombotic syndrome develops in 20–50% of proximal DVT cases → chronic venous insufficiency, skin changes, venous ulceration.
Unusual-site thrombosis (cerebral, portal, mesenteric, hepatic, renal veins) is a hallmark of inherited thrombophilias including Protein C deficiency.
Warfarin-induced skin necrosis is a classic and feared complication — caused by the interaction between pre-existing Protein C deficiency and the pharmacokinetics of warfarin (rapid Protein C depletion before procoagulant factors fall). Prevented by mandatory heparin bridging ^[2] ^[22].
Neonatal purpura fulminans in homozygous deficiency is fatal without emergent Protein C concentrate replacement. Survivors may have permanent neurological, skin, and limb sequelae.
Anticoagulant-related bleeding is the main treatment complication — requires lifelong vigilance, patient education, and knowledge of reversal agents.
Oestrogen-containing contraceptives are absolutely contraindicated (synergistic VTE risk) ^[6] ^[14].
Protein C deficiency can cause or contribute to DIC (homozygous inherited or acquired severe deficiency) → multi-organ dysfunction including AKI, liver failure, ARDS, adrenal failure (Waterhouse-Friderichsen syndrome) ^[2].

Active Recall - Protein C Deficiency: Complications

References

^[1] Senior notes: Block A - Leg swelling and chest pain: deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (Inherited thrombophilia sections on Protein C, Protein S, Antithrombin deficiency; Acquired deficiencies) ^[2] Senior notes: Maksim Medicine Notes.pdf (Thrombophilia screening, DIC clinical features and organ dysfunction, purpura fulminans, p.165) ^[4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (DVT/PE description — death from RV failure; nephrotic syndrome complications: hypercoagulability) ^[6] Senior notes: Ryan Ho Respiratory.pdf (PE risk factors, OCP 2–4× risk) ^[7] Senior notes: Ryan Ho Neurology.pdf (Cerebrovascular disease, hypercoagulability: Protein C/S deficiency) ^[14] Lecture slides: Respiratory Two cases of acute shortness of breath - case 1.pdf (Predisposing causes of DVT and PE; higher level of thrombosis → greater risk of embolisation) ^[17] Senior notes: Ryan Ho Haemtology.pdf (Thrombophilia management table; VTE anticoagulation; pregnancy anticoagulation) ^[21] Senior notes: Introduction to Clinical pharmacology (I) (Pharmaco-Genomics, Precision Medicine).pdf (Warfarin pharmacogenomics, VKORC1, CYP variability — 30% of warfarin response) ^[22] Senior notes: Maksim Surgery Notes.pdf (Perioperative warfarin management, bridging with LMWH, p.26) ^[24] Senior notes: Block A - Abdominal distension: ascites and cirrhosis.pdf (Portal vein thrombosis complications: increased variceal bleeding, ascites, cavernous transformation) ^[25] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (DIC causes table: hereditary Protein C deficiency listed; DIC laboratory features)

High Yield Summary

Protein C is a vitamin K–dependent natural anticoagulant synthesized in the liver. When activated by thrombin-thrombomodulin complex, it (with cofactor Protein S) inactivates Factor Va and Factor VIIIa, putting the brakes on thrombin generation.
Inherited Protein C deficiency is autosomal dominant; prevalence ~1 in 200–500; OR for VTE ~7.5 (intermediate severity: AT deficiency > Protein C deficiency > Protein S deficiency).
Two types: Type I (quantitative — ↓ antigen and activity) and Type II (qualitative — normal antigen, ↓ activity).
Heterozygous patients present with VTE (DVT, PE, unusual-site thrombosis) typically at a young age (10–50 years). Homozygous patients present as neonates with purpura fulminans.
Warfarin-induced skin necrosis is a classic association — caused by rapid depletion of Protein C (short half-life ~6–8 hours) before procoagulant factors fall → transient hypercoagulable state. Always bridge with heparin when starting warfarin.
Standard PT/APTT are normal in isolated Protein C deficiency. Must specifically order Protein C activity (and antigen for typing).
Do not screen for thrombophilia during acute thrombosis or while on anticoagulants — levels are falsely affected.
In Hong Kong/Chinese populations, Factor V Leiden and Prothrombin G20210A are extremely rare → Protein C, Protein S, and Antithrombin deficiencies carry relatively greater diagnostic importance among inherited thrombophilias.

High Yield Summary — Differential Diagnosis

The "Big Three" inherited thrombophilias relevant to Hong Kong Chinese patients are Protein C deficiency, Protein S deficiency, and Antithrombin deficiency. Factor V Leiden and Prothrombin G20210A are essentially absent in Chinese populations.
Always exclude acquired causes of low Protein C (warfarin, liver disease, DIC, acute thrombosis, vitamin K deficiency, sepsis) before labelling a patient as having inherited Protein C deficiency.
APLS is the most important acquired thrombophilia to distinguish — it causes both arterial and venous thrombosis plus recurrent pregnancy loss, and is diagnosed by persistent antiphospholipid antibodies.
Malignancy is the single most important cause of unprovoked VTE overall — always consider occult malignancy screening in older patients with new VTE.
Warfarin-induced skin necrosis specifically points to Protein C (or Protein S) deficiency; heparin resistance specifically points to Antithrombin deficiency*.
Thrombophilia testing must be timed correctly: not during acute thrombosis, and not while on anticoagulants.

High Yield Summary — Diagnostics

Primary diagnostic test: Protein C activity (chromogenic assay) — this is the screening test. If normal, Protein C deficiency is excluded.
Typing: Add Protein C antigen. Type I = low antigen + low activity; Type II = normal antigen + low activity. ^[1]
PT and APTT are NORMAL in isolated Protein C deficiency — routine coagulation screening will miss it.
Never test during acute VTE or while on anticoagulants. Wait ≥2–4 weeks post-event; stop warfarin ≥2 weeks, DOAC ≥2 days. ^[2]
Always exclude acquired causes: warfarin, liver disease, DIC, vitamin K deficiency, sepsis, nephrotic syndrome, pregnancy.
Confirm with repeat testing on a separate occasion. Screen family members. Consider PROC gene sequencing for definitive diagnosis.
In Hong Kong Chinese patients, Factor V Leiden PCR and Prothrombin G20210A PCR can generally be omitted ^[11] — focus on Protein C, Protein S, Antithrombin, and APLS markers.
Thrombophilia screening tests: Protein C, Protein S, APCR, AT, Factor V Leiden PCR, Prothrombin G20210A mutation, APLS markers (anti-cardiolipin, lupus anticoagulant, anti-β2-GPI antibody). ^[2]

High Yield Summary — Management

Acute VTE: Start parenteral anticoagulation (LMWH or UFH) immediately. Massive PE → thrombolysis if no contraindications; ICU care.
Long-term anticoagulation: DOACs are now preferred first-line (no risk of warfarin-induced skin necrosis; no INR monitoring). Warfarin remains an option but MUST be bridged with heparin and started at low dose.
Warfarin in Protein C deficiency → ALWAYS bridge with heparin; NEVER start warfarin alone ^[22]. Warfarin-induced skin necrosis occurs days 3–5 due to rapid Protein C depletion.
Duration: anticoagulation should continue indefinitely after first unprovoked VTE ^[17]. Asymptomatic carriers do not need routine anticoagulation.
Prophylactic anticoagulation in pregnancy, surgery, or post-VTE ^[17] ^[11]. Pregnancy: use LMWH throughout (warfarin teratogenic, DOACs contraindicated); cover up to 6 weeks post-partum.
Homozygous neonatal purpura fulminans: Protein C concentrate (Ceprotin®) is life-saving; FFP as alternative; followed by lifelong anticoagulation.
Oestrogen-containing contraceptives are absolutely contraindicated in Protein C deficiency (synergistic VTE risk).
Family screening and genetic counselling are integral parts of management.

High Yield Summary — Complications

DVT and PE are the most common complications. Patients die from RV failure in PE, not hypoxaemia ^[4]. The higher the level of venous thrombosis, the greater the risk of embolisation ^[14].
Post-thrombotic syndrome develops in 20–50% of proximal DVT cases → chronic venous insufficiency, skin changes, venous ulceration.
Unusual-site thrombosis (cerebral, portal, mesenteric, hepatic, renal veins) is a hallmark of inherited thrombophilias including Protein C deficiency.
Warfarin-induced skin necrosis is a classic and feared complication — caused by the interaction between pre-existing Protein C deficiency and the pharmacokinetics of warfarin (rapid Protein C depletion before procoagulant factors fall). Prevented by mandatory heparin bridging ^[2] ^[22].
Neonatal purpura fulminans in homozygous deficiency is fatal without emergent Protein C concentrate replacement. Survivors may have permanent neurological, skin, and limb sequelae.
Anticoagulant-related bleeding is the main treatment complication — requires lifelong vigilance, patient education, and knowledge of reversal agents.
Oestrogen-containing contraceptives are absolutely contraindicated (synergistic VTE risk) ^[6] ^[14].
Protein C deficiency can cause or contribute to DIC (homozygous inherited or acquired severe deficiency) → multi-organ dysfunction including AKI, liver failure, ARDS, adrenal failure (Waterhouse-Friderichsen syndrome) ^[2].

Protein C Deficiency

1. Definition

2. Epidemiology

2.1 Prevalence

2.2 Ethnic Considerations (Hong Kong Focus)

2.3 Age and Sex

2.4 Risk of Thrombosis

3. Anatomy and Function: The Protein C Anticoagulant Pathway

3.1 Where is Protein C Synthesized?

3.2 What is Protein C?

3.3 Activation of Protein C

3.4 Function of Activated Protein C (APC)

3.5 Conceptual Diagram of the Protein C Anticoagulant Pathway

4. Etiology

4.1 Inherited Protein C Deficiency

4.2 Acquired Protein C Deficiency

5. Pathophysiology

5.1 How Does Protein C Deficiency Cause Thrombosis?

5.2 Why Predominantly Venous (not Arterial) Thrombosis?

5.3 Purpura Fulminans (Homozygous Protein C Deficiency)

5.4 Relationship to Factor V Leiden (Activated Protein C Resistance)

6. Classification

6.1 By Etiology

6.2 By Type (Inherited)

6.3 By Zygosity

7. Clinical Features

7.1 Symptoms

7.1.1 Heterozygous Protein C Deficiency

7.1.2 Homozygous Protein C Deficiency

7.2 Signs

7.3 What Protein C Deficiency Does NOT Typically Cause

8. Thrombophilia Screening — When and How

8.1 Indications for Thrombophilia Screening

8.2 Timing of Testing

8.3 Thrombophilia Panel

8.4 Effect on Standard Coagulation Tests

9. Integration with Coagulation Cascade Concepts

9.1 Where Protein C Fits in the Cascade

9.2 The Natural Anticoagulant Systems (Summary Table)

10. Summary of Key Concepts (Pre-DDx/Ix/Mx Section)

Active Recall - Protein C Deficiency

References

Level 1: Differential Diagnosis of the Thrombophilic State (Why is this patient clotting?)

A. Inherited Thrombophilias

B. Acquired Thrombophilias

Level 2: Differential Diagnosis of a Low Protein C Level on Lab Testing

Distinguishing Protein C Deficiency from Its Closest Mimics

Protein C Deficiency vs. Protein S Deficiency

Protein C Deficiency vs. Antithrombin Deficiency

Protein C Deficiency vs. Antiphospholipid Syndrome (APLS)

Differential Diagnosis Algorithm

Summary Table: Differential Diagnosis at a Glance

Active Recall - Protein C Deficiency: Differential Diagnosis

1. Diagnostic Criteria for Protein C Deficiency

1.1 Laboratory Diagnostic Framework

1.2 Reference Ranges and Interpretation

1.3 Timing of Thrombophilia Testing

2. Diagnostic Algorithm

3. Investigation Modalities

3.1 Specific Protein C Assays

3.2 Complete Thrombophilia Panel

3.3 Standard Coagulation Tests (Baseline)

3.4 Investigations to Assess for Consequences of Protein C Deficiency (VTE Workup)

3.5 Investigations to Exclude Acquired Causes of Low Protein C

3.6 Mixing Study — When Is It Relevant?

4. Interpretation Framework: Putting It All Together

5. Summary Diagnostic Algorithm (Simplified Clinical Pathway)

Active Recall - Protein C Deficiency: Diagnosis and Investigations

1. General Management Principles

2. Management Algorithm

3. Acute VTE Management in Protein C Deficiency

3.1 Initial Parenteral Anticoagulation

3.2 Massive PE with Haemodynamic Instability

4. Transition to Long-Term Oral Anticoagulation

4.1 Direct Oral Anticoagulants (DOACs)

4.2 Warfarin (Vitamin K Antagonist)

4.3 Warfarin vs DOAC — Decision Framework for Protein C Deficiency

5. Duration of Anticoagulation

6. Prophylactic Management (Asymptomatic Carriers and High-Risk Situations)

6.1 Perioperative Thromboprophylaxis